- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on February 06, 2012
b3c newswire
>IDEA Bio-Medical Sells HTS/HCS Cell Imaging System to The Medical University of South CarolinaB3C newswire (http://www.b3cnewswire.com/home.html) - IDEA Bio-Medical Ltd. (http://www.idea-bio.com) and The Medical University of South Carolina (MUSC) announced today that they have completed the sale of IDEA Bio-Medical’s breakthrough Hermes WiScan® system (http://www.idea-bio.com/?_url=products) to MUSC’s Center for Drug Discovery. Hermes WiScan® is a breakthrough biological cell imaging desktop system that enables researchers, at all levels, to run a wide variety of biologi...
>Biotage Introduces Biotage® SNAP Ultra High Performance Flash Chromatography CartridgesB3C newswire (http://www.b3cnewswire.com/home.html) / – Biotage (http://www.biotage.com) (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced the new Biotage® SNAP Ultra high performance flash chromatography cartridges utilizing Biotage® HP-Sphere™ spherical silica. Biotage® SNAP Ultra is available in a wide range of sizes from 10 g – 340 g. Biotage® HP-Sphere™ is chromatographically tested proprietary s...
>Definiens Strengthens Leadership with Key Appointment Former Aperio Executive and Digital Pathology Market Expert, Dr. Martin Stuart, Joins Executive Team Munich, Germany, January 31, 2012 B3C newswire (http://www.b3cnewswire.com/home.html) - Definiens (http://www.definiens.com/), the global leader in Health Image Intelligence and Quantitative Digital Pathology, has appointed Martin Stuart (http://www.definiens.com/about-definiens/our-company/management-team.html), PhD, as its Executive Vice President and General Manager North America and Asi...
>Roche Diagnostics Announces Dan Zabrowski as New Head of Roche Applied Science Penzberg, Germany, January 31, 2012 B3C newswire (http://www.b3cnewswire.com/home.html) - As of February 1, 2012, Dan Zabrowski is Head of Roche Applied Science in the Diagnostics Division, located in Penzberg, Germany. He succeeds Paul Brown who has led Roche Applied Science since September 2011. Dan Zabrowski will report to Daniel O’Day, COO Roche Diagnostics. Dan recently served as Global Head of Roche Partnering and was a member of the Roche Corporate Executive Committee and Chug...
>Rentschler Announces 2. Laupheimer Zelltage on Industrial Cell Culture TechnologyB3C newswire (http://www.b3cnewswire.com/home.html) - Rentschler Biotechnologie GmbH (http://www.rentschler.de/index.php?L=1) is pleased to announce the second Laupheimer Zelltage, a biennial industrial cell culture technology conference to be held on June 11-12, 2012 at Laupheim's historical castle, Schloss Gro?aupheim. The aim of the Laupheimer Zelltage conferences is to provide comprehensive scientific updates on cutting-edge technologies and to discuss application-oriented topics as a mea...
>IDEA Bio-Medical Sells HTS/HCS Cell Imaging System to The Medical University of South CarolinaB3C newswire (http://www.b3cnewswire.com/home.html) - IDEA Bio-Medical Ltd. (http://www.idea-bio.com) and The Medical University of South Carolina (MUSC) announced today that they have completed the sale of IDEA Bio-Medical’s breakthrough Hermes WiScan® system (http://www.idea-bio.com/?_url=products) to MUSC’s Center for Drug Discovery. Hermes WiScan® is a breakthrough biological cell imaging desktop system that enables researchers, at all levels, to run a wide variety of biologi...
>Biotage Introduces Biotage® SNAP Ultra High Performance Flash Chromatography CartridgesB3C newswire (http://www.b3cnewswire.com/home.html) / – Biotage (http://www.biotage.com) (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced the new Biotage® SNAP Ultra high performance flash chromatography cartridges utilizing Biotage® HP-Sphere™ spherical silica. Biotage® SNAP Ultra is available in a wide range of sizes from 10 g – 340 g. Biotage® HP-Sphere™ is chromatographically tested proprietary s...
>Definiens Strengthens Leadership with Key Appointment Former Aperio Executive and Digital Pathology Market Expert, Dr. Martin Stuart, Joins Executive Team Munich, Germany, January 31, 2012 B3C newswire (http://www.b3cnewswire.com/home.html) - Definiens (http://www.definiens.com/), the global leader in Health Image Intelligence and Quantitative Digital Pathology, has appointed Martin Stuart (http://www.definiens.com/about-definiens/our-company/management-team.html), PhD, as its Executive Vice President and General Manager North America and Asi...
>Roche Diagnostics Announces Dan Zabrowski as New Head of Roche Applied Science Penzberg, Germany, January 31, 2012 B3C newswire (http://www.b3cnewswire.com/home.html) - As of February 1, 2012, Dan Zabrowski is Head of Roche Applied Science in the Diagnostics Division, located in Penzberg, Germany. He succeeds Paul Brown who has led Roche Applied Science since September 2011. Dan Zabrowski will report to Daniel O’Day, COO Roche Diagnostics. Dan recently served as Global Head of Roche Partnering and was a member of the Roche Corporate Executive Committee and Chug...
>Rentschler Announces 2. Laupheimer Zelltage on Industrial Cell Culture TechnologyB3C newswire (http://www.b3cnewswire.com/home.html) - Rentschler Biotechnologie GmbH (http://www.rentschler.de/index.php?L=1) is pleased to announce the second Laupheimer Zelltage, a biennial industrial cell culture technology conference to be held on June 11-12, 2012 at Laupheim's historical castle, Schloss Gro?aupheim. The aim of the Laupheimer Zelltage conferences is to provide comprehensive scientific updates on cutting-edge technologies and to discuss application-oriented topics as a mea...
BioSpace
>Cardinal Health, Inc. Plans $90 Million in China Acquisitions February 3, 2012 -- Cardinal Health, the US-based drug distributor, plans to make $90 million in China acquisitions to bolster its geographic coverage in mainland China. In addition, Cardinal said it is expanding its China product offerings to include medical products, lab equipment and other supplies. Cardinal bought a distribution foothold the PRC market in late 2010 by paying $470 million for Zuellig...
>Gilead Sciences, Inc. Soars on Positive Data From Experimental Hepatitis C Drug; Stock Rises +4.77(9.68%) @ 1:09PM EST Gilead Sciences Inc. (GILD), the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained in extended trading after saying one of the therapies produced positive clinical trial results. Patients with genotype 1 hepatitis C -- the most common in North America -- had no detectable signs of the virus after four weeks on the drug, PSI-7977, Norbert Bischofberger...
>Erratic Heart Rhythm May Account for Some Unexplained Strokes, Henry Ford Hospital Study Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012.
>Merck & Co., Inc. Swings to Profit on Fewer Charges, Sales Growth Merck & Co. swung to a fourth-quarter profit from a year-earlier loss that was weighed down by an asset write-down for a drug-research setback, while sales inched up 2%. The Whitehouse Station, N.J., drug maker issued a forecast for full-year 2012 results that leaves room for earnings growth, while sales are expected to be flat or down due to the impending loss of U.S. patent protection for its top...
>Identical Twins Reveal Mechanisms Behind Aging, Uppsala Universitet Study In a recent study led by Uppsala University, the researchers compared the DNA of identical (monozygotic) twins of different age. They could show that structural modifications of the DNA, where large or small DNA segments change direction, are duplicated or completely lost are more common in older people. The results may in part explain why the immune system is impaired with age.
>Cardinal Health, Inc. Plans $90 Million in China Acquisitions February 3, 2012 -- Cardinal Health, the US-based drug distributor, plans to make $90 million in China acquisitions to bolster its geographic coverage in mainland China. In addition, Cardinal said it is expanding its China product offerings to include medical products, lab equipment and other supplies. Cardinal bought a distribution foothold the PRC market in late 2010 by paying $470 million for Zuellig...
>Gilead Sciences, Inc. Soars on Positive Data From Experimental Hepatitis C Drug; Stock Rises +4.77(9.68%) @ 1:09PM EST Gilead Sciences Inc. (GILD), the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained in extended trading after saying one of the therapies produced positive clinical trial results. Patients with genotype 1 hepatitis C -- the most common in North America -- had no detectable signs of the virus after four weeks on the drug, PSI-7977, Norbert Bischofberger...
>Erratic Heart Rhythm May Account for Some Unexplained Strokes, Henry Ford Hospital Study Occasional erratic heart rhythms appear to cause about one-fifth of strokes for which a cause is not readily established, according to research presented at the American Stroke Association's International Stroke Conference 2012.
>Merck & Co., Inc. Swings to Profit on Fewer Charges, Sales Growth Merck & Co. swung to a fourth-quarter profit from a year-earlier loss that was weighed down by an asset write-down for a drug-research setback, while sales inched up 2%. The Whitehouse Station, N.J., drug maker issued a forecast for full-year 2012 results that leaves room for earnings growth, while sales are expected to be flat or down due to the impending loss of U.S. patent protection for its top...
>Identical Twins Reveal Mechanisms Behind Aging, Uppsala Universitet Study In a recent study led by Uppsala University, the researchers compared the DNA of identical (monozygotic) twins of different age. They could show that structural modifications of the DNA, where large or small DNA segments change direction, are duplicated or completely lost are more common in older people. The results may in part explain why the immune system is impaired with age.
BioSpace - Breaking News
>ISCTM Pushes for Innovation in the Development of Novel Therapies for CNS Disorders WASHINGTON--(BUSINESS WIRE)--In a continuation of its mission to address the crisis in CNS drug development, the International Society for CNS Clinical Trials and Methodology (ISCTM) will gather this month for its annual meeting in Washington, D.C. Despite large unmet clinical needs, CNS drugs continue to take longer to develop than other therapies, longer to be reviewed by the FDA, and are nearly...
>Statement from Susan G. Komen for the Cure Board of Directors and Founder and CEO DALLAS--(BUSINESS WIRE)--We want to apologize to the American public for recent decisions that cast doubt upon our commitment to our mission of saving womens lives.The events of this week have been deeply unsettling for our supporters, partners and friends and all of us at Susan G. Komen. We have been distressed at the presumption that the changes made to our funding criteria were done...
>GENFIT Corp. Release: The GFT505-210-6 Study Reaches All Its Efficacy Objectives With No Adverse Effects Lille (France), Cambridge (Massachusetts, United States), February 3rd, 2012 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that the GFT505-210-6** Phase II clinical study has reached all its...
>Positive Data Presented on Athersys, Inc.' MultiStem to Treat Stroke CLEVELAND and NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) Medical School presented new research results this morning at the American Heart Association International Stroke Conference that highlight the role of the spleen in the mechanisms underlying how MultiStem, a novel allogenic stem cell therapy being...
>Watson Pharmaceuticals, Inc. Provides Update on Generic Lidoderm(R) Application PARSIPPANY, N.J., Feb. 3, 2012 /PRNewswire/ -- In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc. (NYSE: WPI) today issued the following statement:"Watson's...
>ISCTM Pushes for Innovation in the Development of Novel Therapies for CNS Disorders WASHINGTON--(BUSINESS WIRE)--In a continuation of its mission to address the crisis in CNS drug development, the International Society for CNS Clinical Trials and Methodology (ISCTM) will gather this month for its annual meeting in Washington, D.C. Despite large unmet clinical needs, CNS drugs continue to take longer to develop than other therapies, longer to be reviewed by the FDA, and are nearly...
>Statement from Susan G. Komen for the Cure Board of Directors and Founder and CEO DALLAS--(BUSINESS WIRE)--We want to apologize to the American public for recent decisions that cast doubt upon our commitment to our mission of saving womens lives.The events of this week have been deeply unsettling for our supporters, partners and friends and all of us at Susan G. Komen. We have been distressed at the presumption that the changes made to our funding criteria were done...
>GENFIT Corp. Release: The GFT505-210-6 Study Reaches All Its Efficacy Objectives With No Adverse Effects Lille (France), Cambridge (Massachusetts, United States), February 3rd, 2012 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that the GFT505-210-6** Phase II clinical study has reached all its...
>Positive Data Presented on Athersys, Inc.' MultiStem to Treat Stroke CLEVELAND and NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) Medical School presented new research results this morning at the American Heart Association International Stroke Conference that highlight the role of the spleen in the mechanisms underlying how MultiStem, a novel allogenic stem cell therapy being...
>Watson Pharmaceuticals, Inc. Provides Update on Generic Lidoderm(R) Application PARSIPPANY, N.J., Feb. 3, 2012 /PRNewswire/ -- In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc. (NYSE: WPI) today issued the following statement:"Watson's...
Biotech News - Business Wire
>Design Concepts, Inc. Welcomes Seng Weiland, Strategic Account ManagerMADISON, Wis.--(BUSINESS WIRE)--Design Concepts expands business development unit with the addition of Seng Weiland, strategic account manager.
>Research and Markets: International Directory of Biotechnology Companies 2012: a must-have for anyone who needs to find contacts in the biotechnology sector worldwideDUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9636f0/international_dire) has announced the addition of the "International Directory of Biotechnology Companies 2012" directory to their offering. The International Directory of Biotechnology Companies 2012 is one of the most comprehensive and accurate Directory of companies and executives in the biotechnology industry that have ever been published. It contains more than 3,000 biotechnology companies an...
>Arcadia?????????450???????????????????????????????????--(BUSINESS WIRE)--(??????)--????????????????????????????Arcadia Biosciences, Inc.?????????????????????U.S. Agency for International Development?USAID???5??450??????????????????????????????????????????????Arcadia???????????????????????????????????Feed the Future?????? ??????????????????????????????150????200????????????????????????100?????????????????????????????????????53%???????????????????????????????2.5?3????????????????4??????????????????????18%????????GDP?????70%???????????????????...
>Natera's Non-Invasive Prenatal Diagnostic to Detect Down Syndrome, Trisomy 13, Trisomy 18 and Certain Sex Chromosome Abnormalities in the First Trimester of PregnancyREDWOOD CITY, Calif.--(BUSINESS WIRE)--Natera, formerly known as Gene Security Network, today announced that details about the breadth of the company?s non-invasive prenatal diagnostic test will be disclosed in presentations during the Society for Maternal-Fetal Medicine?s 32nd Annual Meeting, February 6-11, in Dallas. Natera?s non-invasive prenatal diagnostic test is currently being evaluated in a clinical trial for detection of multiple disorders, including Trisomy 21 (Down syndrome), Triso...
>Sirona Reports Fiscal 2012 First Quarter ResultsLONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the quarter ended December 31, 2011. First Quarter Fiscal 2012 vs. First Quarter Fiscal 2011 Financial Results Revenue was $258.1 million, an increase of $22.5 million or up 9.5% (up 10.2% on a constant currency basis), with growth rates for the Company's business segments as follows: Imaging Systems increased 23.8% (up 24.3% constant currency); Instruments i...
>Design Concepts, Inc. Welcomes Seng Weiland, Strategic Account ManagerMADISON, Wis.--(BUSINESS WIRE)--Design Concepts expands business development unit with the addition of Seng Weiland, strategic account manager.
>Research and Markets: International Directory of Biotechnology Companies 2012: a must-have for anyone who needs to find contacts in the biotechnology sector worldwideDUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9636f0/international_dire) has announced the addition of the "International Directory of Biotechnology Companies 2012" directory to their offering. The International Directory of Biotechnology Companies 2012 is one of the most comprehensive and accurate Directory of companies and executives in the biotechnology industry that have ever been published. It contains more than 3,000 biotechnology companies an...
>Arcadia?????????450???????????????????????????????????--(BUSINESS WIRE)--(??????)--????????????????????????????Arcadia Biosciences, Inc.?????????????????????U.S. Agency for International Development?USAID???5??450??????????????????????????????????????????????Arcadia???????????????????????????????????Feed the Future?????? ??????????????????????????????150????200????????????????????????100?????????????????????????????????????53%???????????????????????????????2.5?3????????????????4??????????????????????18%????????GDP?????70%???????????????????...
>Natera's Non-Invasive Prenatal Diagnostic to Detect Down Syndrome, Trisomy 13, Trisomy 18 and Certain Sex Chromosome Abnormalities in the First Trimester of PregnancyREDWOOD CITY, Calif.--(BUSINESS WIRE)--Natera, formerly known as Gene Security Network, today announced that details about the breadth of the company?s non-invasive prenatal diagnostic test will be disclosed in presentations during the Society for Maternal-Fetal Medicine?s 32nd Annual Meeting, February 6-11, in Dallas. Natera?s non-invasive prenatal diagnostic test is currently being evaluated in a clinical trial for detection of multiple disorders, including Trisomy 21 (Down syndrome), Triso...
>Sirona Reports Fiscal 2012 First Quarter ResultsLONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the quarter ended December 31, 2011. First Quarter Fiscal 2012 vs. First Quarter Fiscal 2011 Financial Results Revenue was $258.1 million, an increase of $22.5 million or up 9.5% (up 10.2% on a constant currency basis), with growth rates for the Company's business segments as follows: Imaging Systems increased 23.8% (up 24.3% constant currency); Instruments i...
Biotech News - PR Newswire
>Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis? Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with unfavorable risk, metastatic renal...
>Shifting Healthcare Landscape has put Medical Science Liaisons in Key Role as Relationship Builder for Pharmaceutical IndustryCHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Medical Science Liaisons have become a key link between the pharmaceutical industry and key stakeholders such as thought leaders that drive marketplace success. And the role of MSLs will grow even more in the coming years as the...
>Kensey Nash to Present at the Canaccord Genuity's Musculoskeletal ConferenceEXTON, Pa., Feb. 3, 2012 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the Canaccord Genuity Musculoskeletal Conference held on Tuesday, February 7, 2012 at Parc 55 in San Francisco, California. Joseph W. Kaufmann, Kensey Nash's President and CEO, will...
>Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common StockCHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public...
>3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2011 ResultsSHENYANG, China, Feb. 3, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its...
>Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis? Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with unfavorable risk, metastatic renal...
>Shifting Healthcare Landscape has put Medical Science Liaisons in Key Role as Relationship Builder for Pharmaceutical IndustryCHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Medical Science Liaisons have become a key link between the pharmaceutical industry and key stakeholders such as thought leaders that drive marketplace success. And the role of MSLs will grow even more in the coming years as the...
>Kensey Nash to Present at the Canaccord Genuity's Musculoskeletal ConferenceEXTON, Pa., Feb. 3, 2012 /PRNewswire/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the Canaccord Genuity Musculoskeletal Conference held on Tuesday, February 7, 2012 at Parc 55 in San Francisco, California. Joseph W. Kaufmann, Kensey Nash's President and CEO, will...
>Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common StockCHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public...
>3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2011 ResultsSHENYANG, China, Feb. 3, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its...
Biotechnology - Moreover
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)(Financial News Network On) Here are 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were underperforming. This is what we found:
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)(Financial News Network On) We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at yesterday's price
>NIH Translational Center Should ?Raise All Boats,? BIO SaysExtract not available.
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly updateImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the threemonth period ended December
>Biotechnology to be 21st-century industry: Life Tech CEOClick on the link to read the full article at Xinhua
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)(Financial News Network On) Here are 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were underperforming. This is what we found:
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)(Financial News Network On) We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at yesterday's price
>NIH Translational Center Should ?Raise All Boats,? BIO SaysExtract not available.
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly updateImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the threemonth period ended December
>Biotechnology to be 21st-century industry: Life Tech CEOClick on the link to read the full article at Xinhua
Burrill Report
>Americans Warming to Healthcare Reform Law Though the Obama administration’s healthcare reform law will likely be a key point of debate during the presidential campaign and the Supreme Court is set to consider its constitutionality in June, Americans are slowly starting to warm to some key components of the legislation, according to a new Harris Interactive/HealthDay poll.
>E-Prescriptions Could Improve Patient Adherence Electronic prescribing could help reduce healthcare expenditures by $140 billion to $240 billion over the next decade due to improved patient adherence to medication regimens, according to a new study by Surescripts.
>Drug Supplies and Economics 101According to a new article in The Lancet, ?The Greek Government's austerity drive has inadvertently triggered problems with the country's drug supply, causing shortages of hundreds of medicines.? But it?s not just Greece.
>Big Pharma Declares War on Neglected Diseases The burden of ten neglected tropical diseases on the world’s poorest may be significantly lightened in the decade ahead by a broad partnership struck by global pharmaceutical companies, governments, and non-governmental organizations.
>Two Life Sciences IPOs Debut Below TargetThe IPO market is heating up as social media giant Facebook filed for a $5 billion initial public offering and two more life sciences companies, Cempra and Greenway Medical Technologies, went public. Both companies, however, priced below their target ranges and raised less than they had hoped.
>Americans Warming to Healthcare Reform Law Though the Obama administration’s healthcare reform law will likely be a key point of debate during the presidential campaign and the Supreme Court is set to consider its constitutionality in June, Americans are slowly starting to warm to some key components of the legislation, according to a new Harris Interactive/HealthDay poll.
>E-Prescriptions Could Improve Patient Adherence Electronic prescribing could help reduce healthcare expenditures by $140 billion to $240 billion over the next decade due to improved patient adherence to medication regimens, according to a new study by Surescripts.
>Drug Supplies and Economics 101According to a new article in The Lancet, ?The Greek Government's austerity drive has inadvertently triggered problems with the country's drug supply, causing shortages of hundreds of medicines.? But it?s not just Greece.
>Big Pharma Declares War on Neglected Diseases The burden of ten neglected tropical diseases on the world’s poorest may be significantly lightened in the decade ahead by a broad partnership struck by global pharmaceutical companies, governments, and non-governmental organizations.
>Two Life Sciences IPOs Debut Below TargetThe IPO market is heating up as social media giant Facebook filed for a $5 billion initial public offering and two more life sciences companies, Cempra and Greenway Medical Technologies, went public. Both companies, however, priced below their target ranges and raised less than they had hoped.
CenterWatch - Clinical Trials
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trendCould last Wednesday?s $20 billion Sanofi-aventis acquisition of Genzyme signal the beginning of an industry trend in which big pharmaceutical companies stop buying each other and start buying robust biotechnology firms? Some industry observers think so. ...
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertisingWhen an investigative site does not have enough potential subjects within its own patient base for a particular trial it has taken on, one of the tasks it faces is placing ads in local media outlets. Traditionally, this has involved producing with the ad or hiring talent to do so, obtaining IRB approval for the messages in the ad, determining in which newspaper, TV and/or radio station the ad should run and at what time of day, and then negotiating with those media outlets?often with less tha...
>Technology companies adapt interactive video concepts for clinical trial informed consentInteractive videos, complete with soothing voices, explain hospital surgeries step-by-step, along with the risks and benefits, to enable patients to make informed decisions. Now, producers of these videos are adapting them for the clinical trials space, which for decades has relied on paper documents that often fail to adequately inform prospective volunteers. A number of small companies that have developed interactive technology for hospitals and ophthalmology and cardiology physician practi...
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phasesConsolidation in the investigative-site space continues. CRI Worldwide of Mount Laurel, N.J., has acquired Lifetree Clinical Research of Salt Lake City, Utah, in a cash deal. Both are large, multi-phase sites with early-phase units. With the purchase, CRI now boasts 120 beds. The acquisition, said CRI senior executive Lawrence Brownstein, was spurred by the company?s desire to round out offerings across all phases. CRI, in business 11 years, had grown tired of having to turn away sponsors, he...
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failureA billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research. According to the Pharmaceutical Research Manufacturers of America (PhRMA), the biopharmaceutical research sector invested an estimated $65.3 billion to discover and develop new medicines in ...
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trendCould last Wednesday?s $20 billion Sanofi-aventis acquisition of Genzyme signal the beginning of an industry trend in which big pharmaceutical companies stop buying each other and start buying robust biotechnology firms? Some industry observers think so. ...
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertisingWhen an investigative site does not have enough potential subjects within its own patient base for a particular trial it has taken on, one of the tasks it faces is placing ads in local media outlets. Traditionally, this has involved producing with the ad or hiring talent to do so, obtaining IRB approval for the messages in the ad, determining in which newspaper, TV and/or radio station the ad should run and at what time of day, and then negotiating with those media outlets?often with less tha...
>Technology companies adapt interactive video concepts for clinical trial informed consentInteractive videos, complete with soothing voices, explain hospital surgeries step-by-step, along with the risks and benefits, to enable patients to make informed decisions. Now, producers of these videos are adapting them for the clinical trials space, which for decades has relied on paper documents that often fail to adequately inform prospective volunteers. A number of small companies that have developed interactive technology for hospitals and ophthalmology and cardiology physician practi...
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phasesConsolidation in the investigative-site space continues. CRI Worldwide of Mount Laurel, N.J., has acquired Lifetree Clinical Research of Salt Lake City, Utah, in a cash deal. Both are large, multi-phase sites with early-phase units. With the purchase, CRI now boasts 120 beds. The acquisition, said CRI senior executive Lawrence Brownstein, was spurred by the company?s desire to round out offerings across all phases. CRI, in business 11 years, had grown tired of having to turn away sponsors, he...
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failureA billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research. According to the Pharmaceutical Research Manufacturers of America (PhRMA), the biopharmaceutical research sector invested an estimated $65.3 billion to discover and develop new medicines in ...
Clinical Trials - Business Wire
>Cancer Research Organization Broadcasts Healthy Eating Tips with Top Chefs around the CountryCHICAGO--(BUSINESS WIRE)--Lynette Bisconti, 14-year cancer survivor and president of The Gateway for Cancer Research (SM), makes it her personal mission to help raise awareness about eating cancer-fighting foods.
>ISCTM Pushes for Innovation in the Development of Novel Therapies for CNS DisordersWASHINGTON--(BUSINESS WIRE)--Leaders from FDA, EMA, PDMA, Medco, Mt Sinai hospital among KOLs gathering to tackle challenges in CNS Drug Development
>Se anunciarán los resultados del estudio «Solitaire with the Intention for Thrombectomy (SWIFT)» en el Congreso Internacional de ACV el 3 de febrero--(BUSINESS WIRE)--Covidien: QUIÉN: Jeffrey Saver, Doctor en Medicina SWIFT, Autor principal Profesor de Neurología y Director del UCLA Stroke Center, David Geffen School of Medicine Universidad de California, Los Ángeles QUÉ: Se anunciarán los resultados del estudio clínico Solitaire para trombectomías (SWIFT, Solitaire with the Intention for Thrombectomy) en una conferencia de prensa a las 8:00 (CT), seguidos de una presentación sobre un ensayo clínico reciente a las 12:00 (CT)....
>Les résultats de l'étude SWIFT (Solitaire with the Intention for Thrombectomy) seront annoncés le 3 février lors de la conférence internationale sur les AVC--(BUSINESS WIRE)--Covidien : QUI : Jeffrey Saver, MD Auteur principal de SWIFT Professeur de neurologie et directeur Centre de l'AVC de l'UCLA, École de médecine David Geffen Université de Californie, Los Angeles SUJET : Les résultats de l'étude SWIFT (Solitaire with the Intention for Thrombectomy) seront annoncés lors d'une conférence de presse à 8h00 (HNC) ? qui sera suivie par la présentation d'un récent essai à 12h00 (HNC). Le dispositif de revascularisation Solitaire? FR est...
>Celebrating 50 Years of Breakthroughs: Bascom Palmer Eye Institute Hosts Global Scientific Meeting, Announces Plans to Expand Clinical Trial Access and Collaborative ResearchMIAMI--(BUSINESS WIRE)--Celebrating 50 years of ophthalmic breakthroughs, Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine is building on research advances its founders couldn't have imagined.
>Cancer Research Organization Broadcasts Healthy Eating Tips with Top Chefs around the CountryCHICAGO--(BUSINESS WIRE)--Lynette Bisconti, 14-year cancer survivor and president of The Gateway for Cancer Research (SM), makes it her personal mission to help raise awareness about eating cancer-fighting foods.
>ISCTM Pushes for Innovation in the Development of Novel Therapies for CNS DisordersWASHINGTON--(BUSINESS WIRE)--Leaders from FDA, EMA, PDMA, Medco, Mt Sinai hospital among KOLs gathering to tackle challenges in CNS Drug Development
>Se anunciarán los resultados del estudio «Solitaire with the Intention for Thrombectomy (SWIFT)» en el Congreso Internacional de ACV el 3 de febrero--(BUSINESS WIRE)--Covidien: QUIÉN: Jeffrey Saver, Doctor en Medicina SWIFT, Autor principal Profesor de Neurología y Director del UCLA Stroke Center, David Geffen School of Medicine Universidad de California, Los Ángeles QUÉ: Se anunciarán los resultados del estudio clínico Solitaire para trombectomías (SWIFT, Solitaire with the Intention for Thrombectomy) en una conferencia de prensa a las 8:00 (CT), seguidos de una presentación sobre un ensayo clínico reciente a las 12:00 (CT)....
>Les résultats de l'étude SWIFT (Solitaire with the Intention for Thrombectomy) seront annoncés le 3 février lors de la conférence internationale sur les AVC--(BUSINESS WIRE)--Covidien : QUI : Jeffrey Saver, MD Auteur principal de SWIFT Professeur de neurologie et directeur Centre de l'AVC de l'UCLA, École de médecine David Geffen Université de Californie, Los Angeles SUJET : Les résultats de l'étude SWIFT (Solitaire with the Intention for Thrombectomy) seront annoncés lors d'une conférence de presse à 8h00 (HNC) ? qui sera suivie par la présentation d'un récent essai à 12h00 (HNC). Le dispositif de revascularisation Solitaire? FR est...
>Celebrating 50 Years of Breakthroughs: Bascom Palmer Eye Institute Hosts Global Scientific Meeting, Announces Plans to Expand Clinical Trial Access and Collaborative ResearchMIAMI--(BUSINESS WIRE)--Celebrating 50 years of ophthalmic breakthroughs, Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine is building on research advances its founders couldn't have imagined.
Clinical Trials - PR Newswire
>Stryker stellt die Ergebnisse der prospektiven klinischen Studie TREVO auf der International Stroke Conference vorKALAMAZOO, Michigan, February 3, 2012 /PRNewswire/ -- - Trevo® Pro System stellt gute funktionelle Resultate bei 55% der Patienten wieder her, die von einem schweren akuten isch?schen Schlaganfall betroffen sind Am 2. Februar hat Stryker auf der Late-Breaking Science...
>Evergreen Neurologist Co-Authors New Study Linking Coffee, Genetics and Parkinson's Disease PreventionKIRKLAND, Wash., Feb. 3, 2012 /PRNewswire/ -- A recent study co-authored by Evergreen Healthcare neurologist Dr. Pinky Agarwal finds good news for coffee drinkers: consuming caffeinated coffee may significantly reduce the risk of Parkinson's disease in some men and women...
>Stryker présente les résultats de l'étude clinique prospective TREVO à l'International Stroke ConferenceKALAMAZOO, Michigan, February 3, 2012 /PRNewswire/ -- - 55 % des patients victimes d'un accident vasculaire c?bral isch?que aigu ont obtenu un bon r?ltat fonctionnel gr? au Trevo® Pro System (syst? Trevo® Pro) Lors de la session...
>Stryker presenta los resultados del estudio clínico prospectivo TREVOKALAMAZOO, Michigan, February 3, 2012 /PRNewswire/ -- Stryker presenta los resultados del estudio cl?co prospectivo TREVO en la International Stroke Conference Trevo® Pro System restaura al 55% de los pacientes que padecen derrame isqu?co agudo severo...
>Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary Cancers SymposiumREDWOOD CITY, Calif., Feb. 3, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a large clinical study in prostate cancer evaluating the relationship of microRNAs, a novel class of biomarkers, to clinical outcomes for patients with...
>Stryker stellt die Ergebnisse der prospektiven klinischen Studie TREVO auf der International Stroke Conference vorKALAMAZOO, Michigan, February 3, 2012 /PRNewswire/ -- - Trevo® Pro System stellt gute funktionelle Resultate bei 55% der Patienten wieder her, die von einem schweren akuten isch?schen Schlaganfall betroffen sind Am 2. Februar hat Stryker auf der Late-Breaking Science...
>Evergreen Neurologist Co-Authors New Study Linking Coffee, Genetics and Parkinson's Disease PreventionKIRKLAND, Wash., Feb. 3, 2012 /PRNewswire/ -- A recent study co-authored by Evergreen Healthcare neurologist Dr. Pinky Agarwal finds good news for coffee drinkers: consuming caffeinated coffee may significantly reduce the risk of Parkinson's disease in some men and women...
>Stryker présente les résultats de l'étude clinique prospective TREVO à l'International Stroke ConferenceKALAMAZOO, Michigan, February 3, 2012 /PRNewswire/ -- - 55 % des patients victimes d'un accident vasculaire c?bral isch?que aigu ont obtenu un bon r?ltat fonctionnel gr? au Trevo® Pro System (syst? Trevo® Pro) Lors de la session...
>Stryker presenta los resultados del estudio clínico prospectivo TREVOKALAMAZOO, Michigan, February 3, 2012 /PRNewswire/ -- Stryker presenta los resultados del estudio cl?co prospectivo TREVO en la International Stroke Conference Trevo® Pro System restaura al 55% de los pacientes que padecen derrame isqu?co agudo severo...
>Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary Cancers SymposiumREDWOOD CITY, Calif., Feb. 3, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a large clinical study in prostate cancer evaluating the relationship of microRNAs, a novel class of biomarkers, to clinical outcomes for patients with...
CNN Top Stories
>Philippines issues local tsunami alertA 6.8-magnitude earthquake struck Monday off the third-largest island in the Philippines, prompting the country to issue a tsunami alert for the coastlines near the epicenter.
>Explosion kills sons, husband of missing Utah womanJosh Powell and his two sons died in a blast at Powell's Washington home, a Pierce County sheriff's spokesman said. Utah police previously had identified Powell as the lone "person of interest" in the disappearance of his wife Susan Powell-Cox in 2009.
>Syrian city shelled from dawn to duskAfter world leaders decried the U.N. Security Council's failure to pass a resolution on Syria, reports of violence surged once again in the besieged country.
>Syrian opposition group calls for strikeAfter world leaders decried the U.N. Security Council's failure to pass a resolution on Syria, reports of violence surged once again in the besieged country.
>Explosion kills kids, husband of missing Utah womanJosh Powell and his two sons died in a blast at Powell's Washington home, a Pierce County sheriff's spokesman said. Utah police previously had identified Powell as the lone "person of interest" in the disappearance of his wife Susan Powell-Cox in 2009.
>Philippines issues local tsunami alertA 6.8-magnitude earthquake struck Monday off the third-largest island in the Philippines, prompting the country to issue a tsunami alert for the coastlines near the epicenter.
>Explosion kills sons, husband of missing Utah womanJosh Powell and his two sons died in a blast at Powell's Washington home, a Pierce County sheriff's spokesman said. Utah police previously had identified Powell as the lone "person of interest" in the disappearance of his wife Susan Powell-Cox in 2009.
>Syrian city shelled from dawn to duskAfter world leaders decried the U.N. Security Council's failure to pass a resolution on Syria, reports of violence surged once again in the besieged country.
>Syrian opposition group calls for strikeAfter world leaders decried the U.N. Security Council's failure to pass a resolution on Syria, reports of violence surged once again in the besieged country.
>Explosion kills kids, husband of missing Utah womanJosh Powell and his two sons died in a blast at Powell's Washington home, a Pierce County sheriff's spokesman said. Utah police previously had identified Powell as the lone "person of interest" in the disappearance of his wife Susan Powell-Cox in 2009.
Contract Pharma
>Celerion Adopts Participant? Verification SystemAllows for more effective screening of study participants
>Syntagon Adds Quality Assurance ExpertKöllner to oversee GMP projects and provide stand-alone service
>SCM Pharma to Provide Product for BrePco BioPharma TrialsWill initially produce clinical batches for eight clinical trial sites
>Melbourn Scientific Names Operations DirectorSolomon's new role aims to expand services portfolio
>Financial Report: Gilead SciencesRevenues up 10% in the quarter
>Celerion Adopts Participant? Verification SystemAllows for more effective screening of study participants
>Syntagon Adds Quality Assurance ExpertKöllner to oversee GMP projects and provide stand-alone service
>SCM Pharma to Provide Product for BrePco BioPharma TrialsWill initially produce clinical batches for eight clinical trial sites
>Melbourn Scientific Names Operations DirectorSolomon's new role aims to expand services portfolio
>Financial Report: Gilead SciencesRevenues up 10% in the quarter
FDA Drugs- What's New
>Initiative Partners
>FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML).
>Medication GuidesUpdated list of medication guides.
>FDA Drug Safety Communication: New Boxed Warning and Contraindication for Adcetris (brentuximab vedotin)[1-13-2012] The U.S. Food and Drug Administration (FDA) is notifying the public that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris (brentuximab vedotin).
>FDA Drug Safety Communication: Update: Preliminary findings from ongoing investigations of CardioGen-82[1-12-2012] The U.S. Food and Drug Administration (FDA) is updating healthcare professionals and the public about preliminary findings from ongoing investigations following the voluntary recall of CardioGen-82 on July 25, 2011 by the manufacturer, Bracco Diagnostics, Inc.
>Initiative Partners
>FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML).
>Medication GuidesUpdated list of medication guides.
>FDA Drug Safety Communication: New Boxed Warning and Contraindication for Adcetris (brentuximab vedotin)[1-13-2012] The U.S. Food and Drug Administration (FDA) is notifying the public that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris (brentuximab vedotin).
>FDA Drug Safety Communication: Update: Preliminary findings from ongoing investigations of CardioGen-82[1-12-2012] The U.S. Food and Drug Administration (FDA) is updating healthcare professionals and the public about preliminary findings from ongoing investigations following the voluntary recall of CardioGen-82 on July 25, 2011 by the manufacturer, Bracco Diagnostics, Inc.
FDA News - Business Wire
>FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily ConvenienceWHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET® XR (sitagliptin and metformin hydrochloride (HCl) extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA® (sitagliptin), with extended-release metformin. JANUMET XR provides a convenient once-daily treatment option for healthc...
>OptiNose Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery TechnologyYARDLEY, Pa.--(BUSINESS WIRE)--OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology. ?This filing signals an important milestone in our quest to deliver improved relief t...
>Regulatory Harmonization Institute and Korea Health Industry Development Institute Partner to Launch 2012 Columbus ProjectELMWOOD PARK, N.J.--(BUSINESS WIRE)--The Regulatory Harmonization Institute, Inc. (RHI) an international, not-for-profit association dedicated to global harmonization of drug and medical device regulatory requirements, and the Korea Health Industry Development Institute (KHIDI), the Korean government organization, announced today to partner in support of the 2012 Columbus Project, a Korean government program to boost globalization of Korea?s healthcare industry. KHIDI has enrolled 42 Korean m...
>La FDA acelera la evaluación de un nuevo medicamento para el cáncer de piel, mientras que Cannabis Science ofrece un tratamiento tópico para el carcinoma basocelular sin efectos secundarios aparentesDENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.OB), una empresa biotecnológica de EE.UU. que desarrolla productos de cannabis (marihuana) farmacéutico, está encantado de informar de la noticia de la reciente aprobación de un fármaco para el cáncer de la FDA sitúa a Cannabis Science en una muy buena posición para desarrollar sus soluciones actuales para combatir el cáncer. Erivedge ha recibido una evaluación rápida de seis meses porque no existen tratamientos aprobados para el car...
>Spectranetics Announces Interim Results from German Study Treating Patients with Peripheral In-Stent RestenosisCOLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq:SPNC) today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster® and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg. There is no device currently cleared or approved by the FDA to treat peri...
>FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily ConvenienceWHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET® XR (sitagliptin and metformin hydrochloride (HCl) extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA® (sitagliptin), with extended-release metformin. JANUMET XR provides a convenient once-daily treatment option for healthc...
>OptiNose Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery TechnologyYARDLEY, Pa.--(BUSINESS WIRE)--OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology. ?This filing signals an important milestone in our quest to deliver improved relief t...
>Regulatory Harmonization Institute and Korea Health Industry Development Institute Partner to Launch 2012 Columbus ProjectELMWOOD PARK, N.J.--(BUSINESS WIRE)--The Regulatory Harmonization Institute, Inc. (RHI) an international, not-for-profit association dedicated to global harmonization of drug and medical device regulatory requirements, and the Korea Health Industry Development Institute (KHIDI), the Korean government organization, announced today to partner in support of the 2012 Columbus Project, a Korean government program to boost globalization of Korea?s healthcare industry. KHIDI has enrolled 42 Korean m...
>La FDA acelera la evaluación de un nuevo medicamento para el cáncer de piel, mientras que Cannabis Science ofrece un tratamiento tópico para el carcinoma basocelular sin efectos secundarios aparentesDENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.OB), una empresa biotecnológica de EE.UU. que desarrolla productos de cannabis (marihuana) farmacéutico, está encantado de informar de la noticia de la reciente aprobación de un fármaco para el cáncer de la FDA sitúa a Cannabis Science en una muy buena posición para desarrollar sus soluciones actuales para combatir el cáncer. Erivedge ha recibido una evaluación rápida de seis meses porque no existen tratamientos aprobados para el car...
>Spectranetics Announces Interim Results from German Study Treating Patients with Peripheral In-Stent RestenosisCOLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq:SPNC) today announced six month interim results from the PATENT (Photo-Ablation using the TURBO-Booster® and Excimer Laser for In-Stent Restenosis Treatment) study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis (ISR) in the femoropopliteal artery in the leg. There is no device currently cleared or approved by the FDA to treat peri...
FDA Press Releases
>FDA and industry reach agreement in principle on medical device user feesThe FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595 million in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon.
>FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancerThe U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today?s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.
>FDA takes action against New York cheese manufacturerThe U.S. Food and Drug Administration is asking a federal court to prevent a New York cheese manufacturer from operating because of a history of unsanitary conditions and producing cheese in a facility contaminated with Listeria monocytogenes bacteria.
>FDA approves Kalydeco to treat rare form of cystic fibrosisThe U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
>FDA approves new treatment for most common type of skin cancerToday, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).
>FDA and industry reach agreement in principle on medical device user feesThe FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595 million in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon.
>FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancerThe U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today?s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.
>FDA takes action against New York cheese manufacturerThe U.S. Food and Drug Administration is asking a federal court to prevent a New York cheese manufacturer from operating because of a history of unsanitary conditions and producing cheese in a facility contaminated with Listeria monocytogenes bacteria.
>FDA approves Kalydeco to treat rare form of cystic fibrosisThe U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
>FDA approves new treatment for most common type of skin cancerToday, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).
FDA Vaccines, Blood and Biologics - What's New
>Cord Blood Banking Information for Consumers
>Cord Blood Banking – Information for Consumers
>Cord Blood Banking ââ?¬â?? Information for Consumers
>Influenza Virus Vaccine for the 2011 - 2012 SeasonCumulative 2010/2011 Season Lot Release Status (Updated 10/20/2010)
>Fluzone, Fluzone High-Dose and Fluzone Intradermal
>Cord Blood Banking Information for Consumers
>Cord Blood Banking – Information for Consumers
>Cord Blood Banking ââ?¬â?? Information for Consumers
>Influenza Virus Vaccine for the 2011 - 2012 SeasonCumulative 2010/2011 Season Lot Release Status (Updated 10/20/2010)
>Fluzone, Fluzone High-Dose and Fluzone Intradermal
FierceBiotech
>FDA commish counters industry critics on expert conflict rulesThere's been an ongoing debate in biopharma circles over the impact a shortage of drug experts is having on the FDA's panel review process. But anyone looking for the agency to welcome changes in the rules governing conflicts of interest--which have been keeping some of the experts at bay--can rule out any support from FDA Commissioner Margaret Hamburg. In testimony to Congress this week, Hamburg made it crystal clear that the agency isn't supporting any new legislative initiatives to ease th...
>Idenix gets good news on hep C trial, but can't compete with GileadIdenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster buyouts, the key focus today is on Gilead's ($GILD) surprise acknowledgement that its new hep C favorite scored promising numbers for the genotype 1 patient population. Indenix ($IDIX) and Achillion ($ACHN)--the other biotech most frequently mentio...
>Scoring winners and losers in Japan pharma M&A boutJapan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The Wall Street Journal is reviewing the biggest buyers and seeing who scored the juiciest gains, and who harvested bitter losses. Astellas Pharma, which acquired OSI Pharmaceuticals in 2010, comes out on top. Story
>AstraZeneca's R&D chief in China lays out $100M strategyOne of the hottest trends in the global R&D business in recent years has been Big Pharma's huge investment in China. Among all the emerging countries, China's massive, fast-growing economy has been a magnet for drug developers determined to tap a whole new market. Steve Yang, AstraZeneca's vice president and head of R&D for Asia and emerging markets, sat down with McKinsey recently to map out the company's research strategy. The big lesson Yang offers is that AstraZeneca ($AZN) doesn't want t...
>AstraZeneca's R&D chief in China lays out its $100M strategyOne of the hottest trends in the global R&D business in recent years has been Big Pharma's huge investment in China. Among all the emerging countries, China's massive, fast-growing economy has been a magnet for drug developers determined to tap a whole new market. Steve Yang, AstraZeneca's vice president and head of R&D for Asia and emerging markets, sat down with McKinsey recently to map out the company's research strategy. The big lesson Yang offers is that AstraZeneca doesn't want to simpl...
>FDA commish counters industry critics on expert conflict rulesThere's been an ongoing debate in biopharma circles over the impact a shortage of drug experts is having on the FDA's panel review process. But anyone looking for the agency to welcome changes in the rules governing conflicts of interest--which have been keeping some of the experts at bay--can rule out any support from FDA Commissioner Margaret Hamburg. In testimony to Congress this week, Hamburg made it crystal clear that the agency isn't supporting any new legislative initiatives to ease th...
>Idenix gets good news on hep C trial, but can't compete with GileadIdenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster buyouts, the key focus today is on Gilead's ($GILD) surprise acknowledgement that its new hep C favorite scored promising numbers for the genotype 1 patient population. Indenix ($IDIX) and Achillion ($ACHN)--the other biotech most frequently mentio...
>Scoring winners and losers in Japan pharma M&A boutJapan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The Wall Street Journal is reviewing the biggest buyers and seeing who scored the juiciest gains, and who harvested bitter losses. Astellas Pharma, which acquired OSI Pharmaceuticals in 2010, comes out on top. Story
>AstraZeneca's R&D chief in China lays out $100M strategyOne of the hottest trends in the global R&D business in recent years has been Big Pharma's huge investment in China. Among all the emerging countries, China's massive, fast-growing economy has been a magnet for drug developers determined to tap a whole new market. Steve Yang, AstraZeneca's vice president and head of R&D for Asia and emerging markets, sat down with McKinsey recently to map out the company's research strategy. The big lesson Yang offers is that AstraZeneca ($AZN) doesn't want t...
>AstraZeneca's R&D chief in China lays out its $100M strategyOne of the hottest trends in the global R&D business in recent years has been Big Pharma's huge investment in China. Among all the emerging countries, China's massive, fast-growing economy has been a magnet for drug developers determined to tap a whole new market. Steve Yang, AstraZeneca's vice president and head of R&D for Asia and emerging markets, sat down with McKinsey recently to map out the company's research strategy. The big lesson Yang offers is that AstraZeneca doesn't want to simpl...
FierceBiotech IT
>Startups ease access to online data on medical product side effectsThe FDA has digested huge amounts of data on the hazardous effects of medical products for decades, and some entrepreneurs have set out to turn a profit from the information. Two recently launched startups aim to make FDA records easily searchable for healthcare professionals and individuals, feeding cravings for health information on the web, The Wall Street Journal reported. AdverseEvents (a name that leaves little doubt what business the company is in) offers free online searches on bad dr...
>Google Ventures, VCs backing tech focused on genomics In its examination of the many potential challenges in genomics, Bloomberg made note of how venture capital is playing a role in advancing technologies that aim to tap the full potential of genomic data. Krishna Yeshwant, a partner at Google Ventures, told the news service that Google's ($GOOG) venture unit has placed a "significant" bet on startups in this field. Last year, the group backed Mountain View, CA-based DNAnexus, which provides software for analyzing genomic data, and Cambridge, M...
>Clinical IT outfit upsizes as Big Pharma customers downsize BioClinica ($BIOC) has plans to hire 55 people this year as the provider of clinical trials software and imaging services scales up its operation, which serves companies--such as Pfizer ($PFE)--that are trimming their ranks, The Philadelphia Inquirer reports. Newtown, PA-based BioClinica has been buying up clinical trials software providers over the past several years, capitalizing on the digitization of clinical data that used to be managed with paper-based systems. And part of its business ...
>U.K. genomics database plan faces hurdles Now that the cost of sequencing DNA is quickly plummeting toward $1,000, some scientists in the U.K. are backing a plan to put citizens' genomic data into a national database. Advocates argue that the DNA database would help deliver on the promise of genomics in healthcare, but critics point out the potential high cost of the endeavor and question the utility of the database, The Telegraph reports. The U.K.'s Human Genomics Strategy Group, which has written a report on the topic, is backing t...
>Covance's big IT budget gets thumbs down from analysts Covance ($CVD) wants to reduce annual increases in its information technology budget, but the big CRO told investors Wednesday that it was going to have to make some major investments in the short term to save money in the long term. Yet the dour outlook on earnings for this year weighed on the company's stock price, which sank more than 8% during regular trading Thursday. This year, Covance plans to pump $90 million into revamping its IT, a 17% increase in spending on such technology accordi...
>Startups ease access to online data on medical product side effectsThe FDA has digested huge amounts of data on the hazardous effects of medical products for decades, and some entrepreneurs have set out to turn a profit from the information. Two recently launched startups aim to make FDA records easily searchable for healthcare professionals and individuals, feeding cravings for health information on the web, The Wall Street Journal reported. AdverseEvents (a name that leaves little doubt what business the company is in) offers free online searches on bad dr...
>Google Ventures, VCs backing tech focused on genomics In its examination of the many potential challenges in genomics, Bloomberg made note of how venture capital is playing a role in advancing technologies that aim to tap the full potential of genomic data. Krishna Yeshwant, a partner at Google Ventures, told the news service that Google's ($GOOG) venture unit has placed a "significant" bet on startups in this field. Last year, the group backed Mountain View, CA-based DNAnexus, which provides software for analyzing genomic data, and Cambridge, M...
>Clinical IT outfit upsizes as Big Pharma customers downsize BioClinica ($BIOC) has plans to hire 55 people this year as the provider of clinical trials software and imaging services scales up its operation, which serves companies--such as Pfizer ($PFE)--that are trimming their ranks, The Philadelphia Inquirer reports. Newtown, PA-based BioClinica has been buying up clinical trials software providers over the past several years, capitalizing on the digitization of clinical data that used to be managed with paper-based systems. And part of its business ...
>U.K. genomics database plan faces hurdles Now that the cost of sequencing DNA is quickly plummeting toward $1,000, some scientists in the U.K. are backing a plan to put citizens' genomic data into a national database. Advocates argue that the DNA database would help deliver on the promise of genomics in healthcare, but critics point out the potential high cost of the endeavor and question the utility of the database, The Telegraph reports. The U.K.'s Human Genomics Strategy Group, which has written a report on the topic, is backing t...
>Covance's big IT budget gets thumbs down from analysts Covance ($CVD) wants to reduce annual increases in its information technology budget, but the big CRO told investors Wednesday that it was going to have to make some major investments in the short term to save money in the long term. Yet the dour outlook on earnings for this year weighed on the company's stock price, which sank more than 8% during regular trading Thursday. This year, Covance plans to pump $90 million into revamping its IT, a 17% increase in spending on such technology accordi...
FierceBiotech Research
>Stem cells solve hepatitis C research dilemma It is now possible to develop liverlike cells in the lab from stem cells derived from human tissue, and infect them with hepatitis C. So what, you ask? The finding, by researchers from the Massachusetts Institute of Technology, Rockefeller University and the Medical College of Wisconsin, solves a major problem scientists face when trying to figure out why some people are susceptible to the hard-to-treat infection and others aren't. Ideally, scientists would study liver cells from affected pat...
>Mutated melanoma receptor heightens diabetes riskIt turns out that patients with any of four rare mutations in the MT2 gene become 6 times more likely to develop Type 2 diabetes, according to a research study led by Philippe Froguel of the School of Public Health at Imperial College London. The research builds on a 2008 study at the same institution that found that individuals have a slightly higher risk of getting Type 2 diabetes if they have common variations in the MT2 gene. Details of the new study can be found in Nature Genetics. This ...
>Team finds 2 mutations that cause pediatric brain cancerGlioblastomas are less common in children than in adults but just as lethal. They are fatal tumors that don't respond to chemotherapy and radiation and inflict a particularly nasty death. These facts make a new discovery led by the Research Institute of the McGill University Health Centre in Montreal all the more compelling. Experts have discovered two never-before-known mutations in the histone H3.3 gene that cause as many as 40% of pediatric glioblastomas. Let us pause and consider the impl...
>Meet cancer's latest enemy: grape seed extractOnce again, a common food may contain a cancer cure. This time, grapes have the magic ingredient. Scientists at the University of Colorado Cancer Center and the Skaggs School of Pharmaceutical Sciences used grape seed extract to kill head and neck cancer cells in mice, and the treatment left healthy cells alone, according to UCCC's Colorado Cancer Blogs. Details are published in the journal Carcinogenesis. Here's the short version of what they found: Scientists tested grape seed extract on bo...
>Nearly $11M to fund new Joslin Diabetes Center research facility Diabetes research is getting a significant boost in Boston: The Harvard Medical School-affiliated Joslin Diabetes Center will spend $10.8 million to establish a Translational Center for the Cure of Diabetes, The Boston Globe reports. A state grant supplies about half of the funding, and the rest comes from matching donor contributions. Joslin plans to use the second through fourth floors of its seven-floor hospital for the operation, which will include renovated lab space and a number of new ...
>Stem cells solve hepatitis C research dilemma It is now possible to develop liverlike cells in the lab from stem cells derived from human tissue, and infect them with hepatitis C. So what, you ask? The finding, by researchers from the Massachusetts Institute of Technology, Rockefeller University and the Medical College of Wisconsin, solves a major problem scientists face when trying to figure out why some people are susceptible to the hard-to-treat infection and others aren't. Ideally, scientists would study liver cells from affected pat...
>Mutated melanoma receptor heightens diabetes riskIt turns out that patients with any of four rare mutations in the MT2 gene become 6 times more likely to develop Type 2 diabetes, according to a research study led by Philippe Froguel of the School of Public Health at Imperial College London. The research builds on a 2008 study at the same institution that found that individuals have a slightly higher risk of getting Type 2 diabetes if they have common variations in the MT2 gene. Details of the new study can be found in Nature Genetics. This ...
>Team finds 2 mutations that cause pediatric brain cancerGlioblastomas are less common in children than in adults but just as lethal. They are fatal tumors that don't respond to chemotherapy and radiation and inflict a particularly nasty death. These facts make a new discovery led by the Research Institute of the McGill University Health Centre in Montreal all the more compelling. Experts have discovered two never-before-known mutations in the histone H3.3 gene that cause as many as 40% of pediatric glioblastomas. Let us pause and consider the impl...
>Meet cancer's latest enemy: grape seed extractOnce again, a common food may contain a cancer cure. This time, grapes have the magic ingredient. Scientists at the University of Colorado Cancer Center and the Skaggs School of Pharmaceutical Sciences used grape seed extract to kill head and neck cancer cells in mice, and the treatment left healthy cells alone, according to UCCC's Colorado Cancer Blogs. Details are published in the journal Carcinogenesis. Here's the short version of what they found: Scientists tested grape seed extract on bo...
>Nearly $11M to fund new Joslin Diabetes Center research facility Diabetes research is getting a significant boost in Boston: The Harvard Medical School-affiliated Joslin Diabetes Center will spend $10.8 million to establish a Translational Center for the Cure of Diabetes, The Boston Globe reports. A state grant supplies about half of the funding, and the rest comes from matching donor contributions. Joslin plans to use the second through fourth floors of its seven-floor hospital for the operation, which will include renovated lab space and a number of new ...
FiercePharma
>Botox delivers for Allergan, Dr. Reddy's sees big profit increase during quarterAnother day, another round of earnings calls. Today's roundup includes Allergan, which received a boost from Botox, a widely known wrinkle-fighter that is now garnering approvals around the world for a number of therapeutic uses. Also profiled is rising generics company Dr. Reddy's, which posted its biggest quarter ever. Gilead Sciences and Vertex Pharmaceuticals wrap up the profiles with both boasting gains during the fourth quarter and full-year 2011. Botox was big news for Allergan ($AGN...
>Astellas scores highest in Japanese M&A boutJapan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The Wall Street Journal is reviewing the biggest buyers and seeing who scored the juiciest gains, and who harvested bitter losses. Astellas Pharma, which acquired OSI Pharmaceuticals in 2010, comes out on top. A big reason is OSI's cancer drug Tarceva, which racked up a 55% increase in sales fo...
>FDA talks, but doctors don't necessarily listenPoor FDA. It takes flak every time a drug spawns unexpected side effects. But when it tries to warn doctors about those side effects--and offers advice for preventing them--few physicians are listening. As AMedNews reports, researchers looked at 16 drugs that got new label warnings or were mentioned in "Dear Doctor" letters from 1990 to 2010. And they found that doctors' behavior often changed very little after those cautionary tales were told. When the FDA recommended that patients using aty...
>Gloom for the pharma industry, yes. Doom? NoAstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spate of payroll-cutting news from Novartis ($NVS), Sanofi ($SNY), Teva Pharmaceutical Industries ($TEVA), Takeda Pharmaceutical, and more. And it adds to AstraZeneca's already daunting total of 21,000-plus since 2007. Still, so many government officials and media outlets have been aflutter about the new...
>Mediator probe rolls on with searches at Afssaps, executives' homesThe Mediator scandal in France continues as investigators searched the offices of healthcare regulators Afssaps and the homes of several of its executives. The agency faced a public outcry over its decision to keep the weight-loss drug on the market years after it was pulled in other countries. Report
>Botox delivers for Allergan, Dr. Reddy's sees big profit increase during quarterAnother day, another round of earnings calls. Today's roundup includes Allergan, which received a boost from Botox, a widely known wrinkle-fighter that is now garnering approvals around the world for a number of therapeutic uses. Also profiled is rising generics company Dr. Reddy's, which posted its biggest quarter ever. Gilead Sciences and Vertex Pharmaceuticals wrap up the profiles with both boasting gains during the fourth quarter and full-year 2011. Botox was big news for Allergan ($AGN...
>Astellas scores highest in Japanese M&A boutJapan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The Wall Street Journal is reviewing the biggest buyers and seeing who scored the juiciest gains, and who harvested bitter losses. Astellas Pharma, which acquired OSI Pharmaceuticals in 2010, comes out on top. A big reason is OSI's cancer drug Tarceva, which racked up a 55% increase in sales fo...
>FDA talks, but doctors don't necessarily listenPoor FDA. It takes flak every time a drug spawns unexpected side effects. But when it tries to warn doctors about those side effects--and offers advice for preventing them--few physicians are listening. As AMedNews reports, researchers looked at 16 drugs that got new label warnings or were mentioned in "Dear Doctor" letters from 1990 to 2010. And they found that doctors' behavior often changed very little after those cautionary tales were told. When the FDA recommended that patients using aty...
>Gloom for the pharma industry, yes. Doom? NoAstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spate of payroll-cutting news from Novartis ($NVS), Sanofi ($SNY), Teva Pharmaceutical Industries ($TEVA), Takeda Pharmaceutical, and more. And it adds to AstraZeneca's already daunting total of 21,000-plus since 2007. Still, so many government officials and media outlets have been aflutter about the new...
>Mediator probe rolls on with searches at Afssaps, executives' homesThe Mediator scandal in France continues as investigators searched the offices of healthcare regulators Afssaps and the homes of several of its executives. The agency faced a public outcry over its decision to keep the weight-loss drug on the market years after it was pulled in other countries. Report
FiercePharma Manufacturing
>Executive suite not spared in J&J reorg tied to quality concernsManagement at the factory level feel the heat under any FDA consent decree, but a shake-up at Johnson & Johnson ($JNJ) this week showed that the pressure can extend into the executive suite. Two J&J group chairmen and long-term executives left this week, presumably because of ongoing difficulties in the company's consumer health business, The Wall Street Journal reports. The departures come less than a year after manufacturing problems sparked a revamp that gave them new authority in consumer...
>Medical devicemakers double down on FDAMedical device manufacturers are doubling down on the FDA, agreeing to pay $595 million in fees over 5 years in exchange for promises of more and faster approvals and better communication from the agency. That is about twice what was paid under the program that expires Sept. 30. The FDA said it will hire about 200 people to speed up the process, and an independent consultant to recommend process improvements. Release | Story
>Pfizer suspects 30 packs of contraceptives mispackaged; pulls 1 million just in caseWorkers at a Pfizer ($PFE) plant in upstate New York that makes birth control pills are learning that if you mispackage pills, it can create unwanted problems. Pfizer announced Wednesday that it is recalling 1 million packets, 14 batches of Lo/Ovral-28 pills and 14 batches of its generic counterparts, norgestrel and ethinyl estradiol tablets. The pills were manufactured and packaged by Pfizer but, Bloomberg says, marketed by Akrimax Rx Products under the Akrimax Pharmaceuticals brand. Some pa...
>Roche plant spared from sale runs into GMP issuesA South Carolina plant Roche ($RHHBY) had on the auction block last year has developed manufacturing issues that have interrupted production of its weight control drug Xenical.Health officials in the U.S. and Europe have been notified, and the Swiss company is bringing in an expert to help it get a handle on "Good Manufacturing Practice (GMP) deficiencies discovered during an internal audit," the company said in a statement emailed to FiercePharmaManufacturing. No specifics were given. The Fl...
>Amylin's OH plant prepped for Bydureon's U.S. debutIn anticipation of the U.S. approval of Bydureon, San Diego's Amylin Pharmaceuticals ($AMLN) was already amping up production of the diabetes drug at its West Chester Township, OH, plant where the med was being manufactured for the European market. The company has been making some parts of the drug and holding it for final packaging, a spokeswoman told the Middleton Journal. The drug is now being rolled out for delivery to pharmacies this month. The FDA gave approval of the first once-weekly ...
>Executive suite not spared in J&J reorg tied to quality concernsManagement at the factory level feel the heat under any FDA consent decree, but a shake-up at Johnson & Johnson ($JNJ) this week showed that the pressure can extend into the executive suite. Two J&J group chairmen and long-term executives left this week, presumably because of ongoing difficulties in the company's consumer health business, The Wall Street Journal reports. The departures come less than a year after manufacturing problems sparked a revamp that gave them new authority in consumer...
>Medical devicemakers double down on FDAMedical device manufacturers are doubling down on the FDA, agreeing to pay $595 million in fees over 5 years in exchange for promises of more and faster approvals and better communication from the agency. That is about twice what was paid under the program that expires Sept. 30. The FDA said it will hire about 200 people to speed up the process, and an independent consultant to recommend process improvements. Release | Story
>Pfizer suspects 30 packs of contraceptives mispackaged; pulls 1 million just in caseWorkers at a Pfizer ($PFE) plant in upstate New York that makes birth control pills are learning that if you mispackage pills, it can create unwanted problems. Pfizer announced Wednesday that it is recalling 1 million packets, 14 batches of Lo/Ovral-28 pills and 14 batches of its generic counterparts, norgestrel and ethinyl estradiol tablets. The pills were manufactured and packaged by Pfizer but, Bloomberg says, marketed by Akrimax Rx Products under the Akrimax Pharmaceuticals brand. Some pa...
>Roche plant spared from sale runs into GMP issuesA South Carolina plant Roche ($RHHBY) had on the auction block last year has developed manufacturing issues that have interrupted production of its weight control drug Xenical.Health officials in the U.S. and Europe have been notified, and the Swiss company is bringing in an expert to help it get a handle on "Good Manufacturing Practice (GMP) deficiencies discovered during an internal audit," the company said in a statement emailed to FiercePharmaManufacturing. No specifics were given. The Fl...
>Amylin's OH plant prepped for Bydureon's U.S. debutIn anticipation of the U.S. approval of Bydureon, San Diego's Amylin Pharmaceuticals ($AMLN) was already amping up production of the diabetes drug at its West Chester Township, OH, plant where the med was being manufactured for the European market. The company has been making some parts of the drug and holding it for final packaging, a spokeswoman told the Middleton Journal. The drug is now being rolled out for delivery to pharmacies this month. The FDA gave approval of the first once-weekly ...
FierceVaccines
>Women's own cells could blast breast cancerThe idea of using your own cells to create a vaccine seems to be the ultimate in personalized medicine, and results from a breast cancer trial bring this idea yet another step closer. After receiving just four weeks' treatment with a vaccine based on their own white blood cells, women with ductal carcinoma in situ (DCIS), an early form of breast cancer, showed an immune response, or even complete destruction of their tumors. The vaccine, developed at the Perelman School of Medicine and the Ab...
>Universal flu vaccine might be a step closerDid you get the flu last year? Unfortunately, that won't stop you getting it this year, or next year, or whenever bird flu or swine flu next strikes, because the virus mutates so rapidly. This means that the flu vaccine has to be made each year, based on a simple (and fallible) prediction of what is going to be the next year's prevailing strain. However, work from the Universities of Southampton and Oxford and the CRO Retroscreen Virology might make this annual guessing game a thing of the pa...
>First hookworm vaccine enters clinical trialsHookworms are not good things to have--they arrive through the skin and leave via the gut, and while they are around, they lead to malnutrition and blood loss. As I said, not good. The Infectious Disease Research Institute (IDRI) is working with the Sabin Vaccine Institute on the first clinical trial of a hookworm vaccine to protect people at risk of infection. Hookworms are small parasitic roundworms that get into the body through the skin, causing itching and skin damage, and then travel th...
>Ovarian cancer vaccine clinical trial begins enrollmentOvarian cancer is a steady, silent killer--its diagnosis is easy to miss and there are few options to prevent recurrence after treatment. Australian biotech company Prima BioMed's vaccine, known as Cvac, is in clinical development, and Sarasota Memorial Hospital in the U.S. will be the first site in the world approved to begin enrolling patients in the company's international Phase II trial. The ovarian cancer vaccine is a personalized treatment made from the patient's dendritic cells (white ...
>Study: Gardasil does not cause autoimmune diseaseThere have been anecdotal reports that Gardasil, Merck's ($MRK) human papillomavirus vaccine, causes autoimmune disease. A study of almost 200,000 women over two years may finally scotch this rumor, or at least offer some scientific data to balance out the argument. The two-year study, carried out by Kaiser Permanente researchers, tracked 189,629 Californian women and girls between 9 and 26 years of age with no sign of autoimmune disease for 6 months after they received each dose of Gardasil,...
>Women's own cells could blast breast cancerThe idea of using your own cells to create a vaccine seems to be the ultimate in personalized medicine, and results from a breast cancer trial bring this idea yet another step closer. After receiving just four weeks' treatment with a vaccine based on their own white blood cells, women with ductal carcinoma in situ (DCIS), an early form of breast cancer, showed an immune response, or even complete destruction of their tumors. The vaccine, developed at the Perelman School of Medicine and the Ab...
>Universal flu vaccine might be a step closerDid you get the flu last year? Unfortunately, that won't stop you getting it this year, or next year, or whenever bird flu or swine flu next strikes, because the virus mutates so rapidly. This means that the flu vaccine has to be made each year, based on a simple (and fallible) prediction of what is going to be the next year's prevailing strain. However, work from the Universities of Southampton and Oxford and the CRO Retroscreen Virology might make this annual guessing game a thing of the pa...
>First hookworm vaccine enters clinical trialsHookworms are not good things to have--they arrive through the skin and leave via the gut, and while they are around, they lead to malnutrition and blood loss. As I said, not good. The Infectious Disease Research Institute (IDRI) is working with the Sabin Vaccine Institute on the first clinical trial of a hookworm vaccine to protect people at risk of infection. Hookworms are small parasitic roundworms that get into the body through the skin, causing itching and skin damage, and then travel th...
>Ovarian cancer vaccine clinical trial begins enrollmentOvarian cancer is a steady, silent killer--its diagnosis is easy to miss and there are few options to prevent recurrence after treatment. Australian biotech company Prima BioMed's vaccine, known as Cvac, is in clinical development, and Sarasota Memorial Hospital in the U.S. will be the first site in the world approved to begin enrolling patients in the company's international Phase II trial. The ovarian cancer vaccine is a personalized treatment made from the patient's dendritic cells (white ...
>Study: Gardasil does not cause autoimmune diseaseThere have been anecdotal reports that Gardasil, Merck's ($MRK) human papillomavirus vaccine, causes autoimmune disease. A study of almost 200,000 women over two years may finally scotch this rumor, or at least offer some scientific data to balance out the argument. The two-year study, carried out by Kaiser Permanente researchers, tracked 189,629 Californian women and girls between 9 and 26 years of age with no sign of autoimmune disease for 6 months after they received each dose of Gardasil,...
Health News - BizJournals.com
>ChemoCentryx IPO expected this weekChemoCentryx Inc. is the next Silicon Valley initial public offering expected, with its debut on Nasdaq expected this week. The Mountain View company set a target range last month of $14 to $16 for the 4 million shares it plans to sell in the IPO. The target at the top of the range would bring in $64 million, slightly less than the $69 million the biopharmaceutical company filed for back in October. ChemoCentryx focuses on the treatment of autoimmune diseases, inflammatory disorders ...
>Planned Parenthood holds Arizona fundraiser after Komen flapPlanned Parenthood?s political arm in Arizona will hold a fundraising event next month with Planned Parenthood Federation of America CEO Cecile Richards. The event comes on the heels of the abortion-fueled national controversy involving Planned Parenthood and whether it will receive funding from the Susan G. Komen for the Cure. The March 15 annual luncheon and fundraiser will benefit Planned Parenthood Advocates of Arizona, the political advocacy arm of the women?s health group and abor...
>Slide show: Top 10 regional conventions and trade shows in SeattleConventions and trade shows impact the Puget Sound area economy to the tune of millions of dollars ? and they attract millions of enthusiastic attendees from the region, nation and the world. Some of the more colorful events include the Northwest Flower & Garden Show and two conventions that welcome legions of costume-clad comics fans: Emerald City ComiCon and Sakura-Con. Other exhibitions cater to prospective college students, motorcycle lovers, and engaged couples planning weddings. T...
>Abercrombie to sign organ transplant funding bill into lawHawaii lawmakers on Friday passed legislation for about $1.8 million in emergency funds for kidney and liver transplants in the state. Gov. Neil Abercrombie plans to sign House Bill 608 into law on Saturday at The Queen's Medical Center. The law will appropriate emergency funds, subject to private matching funds, for the transplants, as well as to support a chronic kidney disease management program. Hawaii was left without an organ transplant center after the closure last month of Ha...
>Cempra enjoys modest gain on tradingShares of Chapel Hill drug developer Cempra (Nasdaq: CEMP) opened at $6.20 on its first day of trading as a public company, up 3.3 percent from the IPO price of $6. A total of 8.4 million shares at a price well below the expected $11 to $13. For more, go here. Cempra is headed by CEO Prabha Fernandes.
>ChemoCentryx IPO expected this weekChemoCentryx Inc. is the next Silicon Valley initial public offering expected, with its debut on Nasdaq expected this week. The Mountain View company set a target range last month of $14 to $16 for the 4 million shares it plans to sell in the IPO. The target at the top of the range would bring in $64 million, slightly less than the $69 million the biopharmaceutical company filed for back in October. ChemoCentryx focuses on the treatment of autoimmune diseases, inflammatory disorders ...
>Planned Parenthood holds Arizona fundraiser after Komen flapPlanned Parenthood?s political arm in Arizona will hold a fundraising event next month with Planned Parenthood Federation of America CEO Cecile Richards. The event comes on the heels of the abortion-fueled national controversy involving Planned Parenthood and whether it will receive funding from the Susan G. Komen for the Cure. The March 15 annual luncheon and fundraiser will benefit Planned Parenthood Advocates of Arizona, the political advocacy arm of the women?s health group and abor...
>Slide show: Top 10 regional conventions and trade shows in SeattleConventions and trade shows impact the Puget Sound area economy to the tune of millions of dollars ? and they attract millions of enthusiastic attendees from the region, nation and the world. Some of the more colorful events include the Northwest Flower & Garden Show and two conventions that welcome legions of costume-clad comics fans: Emerald City ComiCon and Sakura-Con. Other exhibitions cater to prospective college students, motorcycle lovers, and engaged couples planning weddings. T...
>Abercrombie to sign organ transplant funding bill into lawHawaii lawmakers on Friday passed legislation for about $1.8 million in emergency funds for kidney and liver transplants in the state. Gov. Neil Abercrombie plans to sign House Bill 608 into law on Saturday at The Queen's Medical Center. The law will appropriate emergency funds, subject to private matching funds, for the transplants, as well as to support a chronic kidney disease management program. Hawaii was left without an organ transplant center after the closure last month of Ha...
>Cempra enjoys modest gain on tradingShares of Chapel Hill drug developer Cempra (Nasdaq: CEMP) opened at $6.20 on its first day of trading as a public company, up 3.3 percent from the IPO price of $6. A total of 8.4 million shares at a price well below the expected $11 to $13. For more, go here. Cempra is headed by CEO Prabha Fernandes.
Health News - CNBC
>Green tea drinkers show less disability with age: study
>Tyson Foods, BB&T, Gilead are market moversStocks that moved substantially or traded heavily Friday on the New York Stock Exchange and Nasdaq Stock Market:
>PerkinElmer rises on 4Q results and outlookShares of PerkinElmer Inc. climbed Friday after the life sciences company posted strong results in the fourth quarter and forecast profit in 2012 greater than analysts had expected.
>Edwards Lifesciences stock falls after 4Q reportShares of Edwards Lifesciences Corp. slid 11 percent Friday, a day after the heart valve maker posted disappointing revenue numbers for the fourth quarter and an outlook that fell short of expectations.
>DEA suspends Cardinal Health license in Florida
>Green tea drinkers show less disability with age: study
>Tyson Foods, BB&T, Gilead are market moversStocks that moved substantially or traded heavily Friday on the New York Stock Exchange and Nasdaq Stock Market:
>PerkinElmer rises on 4Q results and outlookShares of PerkinElmer Inc. climbed Friday after the life sciences company posted strong results in the fourth quarter and forecast profit in 2012 greater than analysts had expected.
>Edwards Lifesciences stock falls after 4Q reportShares of Edwards Lifesciences Corp. slid 11 percent Friday, a day after the heart valve maker posted disappointing revenue numbers for the fourth quarter and an outlook that fell short of expectations.
>DEA suspends Cardinal Health license in Florida
Health News - Fox Business
>Employers Grateful for Proposed Tax Breaks, But Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Employers Grateful for Proposed Tax Breaks, Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Insmed Shares Drop as FDA Halts Study After Rat Test ResultsBiopharmaceutical company, Insmed Incorporated (NYSE:INSM), announced Monday that the U.S. Food and Drug Administration has put the company?s clinical trials for an inhalable antibiotic on hold after reviewing early results from its long-term tests on rats.
>Week Ahead: A Flood Of 2Q EarningsSecond quarter earnings will dominate investors? attention next week, followed closely by housing data.
>Pfizer Drug Raises Heart Attack Risk: StudyNew research shows healthy, middle-aged smokers who take quit-smoking drugs Chantix or Champix have a higher risk of suffering heart attacks.
>Employers Grateful for Proposed Tax Breaks, But Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Employers Grateful for Proposed Tax Breaks, Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Insmed Shares Drop as FDA Halts Study After Rat Test ResultsBiopharmaceutical company, Insmed Incorporated (NYSE:INSM), announced Monday that the U.S. Food and Drug Administration has put the company?s clinical trials for an inhalable antibiotic on hold after reviewing early results from its long-term tests on rats.
>Week Ahead: A Flood Of 2Q EarningsSecond quarter earnings will dominate investors? attention next week, followed closely by housing data.
>Pfizer Drug Raises Heart Attack Risk: StudyNew research shows healthy, middle-aged smokers who take quit-smoking drugs Chantix or Champix have a higher risk of suffering heart attacks.
Inside Industry - Gen
>Agennix Stops Phase II/III Talactoferrin Study in Sepsis Due to Higher Death Rates
>PDUFA V Supporters Try to Sell Congress on Job, Innovation Potential
>Athersys? MultiStem Program Gets $3.6M Boost
>Shire, Sangamo Ink $13M Up-Front Deal for ZFPs against Hemophilia and Monogenic Disorders
>Roche's Cobas Test for Chlamydia and Gonorrhea Granted 510(k) Clearance in U.S.
>Agennix Stops Phase II/III Talactoferrin Study in Sepsis Due to Higher Death Rates
>PDUFA V Supporters Try to Sell Congress on Job, Innovation Potential
>Athersys? MultiStem Program Gets $3.6M Boost
>Shire, Sangamo Ink $13M Up-Front Deal for ZFPs against Hemophilia and Monogenic Disorders
>Roche's Cobas Test for Chlamydia and Gonorrhea Granted 510(k) Clearance in U.S.
Marketwire - Pharma and Biotech
>Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs STOCKHOLM, SWEDEN--(Marketwire - Feb 6, 2012) - Sobi and Biogen Idec have agreed to disclose further details on their agreement regarding development and commercialization of long-lasting recombinant factor VIII and factor IX hemophilia programs, which was restructured in February 2010. Under the new agreement, Biogen Idec assumed full development responsibilities and costs, as well as manufacturing rights. In addition, the cross-royalty rates were reduced and commercial rights for certain...
>Pyng Medical Corp. Announces Bridge Loan VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 3, 2012) - Pyng Medical Corp. (TSX VENTURE:PYT) ("Pyng" or the "Company") today announced a loan (the "Loan") in the amount of US$220,000 from its largest shareholder Excelera Corporation ("Excelera"). The Loan carries interest at 11% per annum, is unsecured, and does not include an equity component. The total principal and interest is due on April 12, 2012.
>Elderly Alerts, Leader in Medical Alert Systems, Educates the Elderly Community via Twitter Through Social Media, Elderly Alerts Educates on the Importance of Having Medical Alert Alarms at Home
>Intergraph(R) Webinars on February 15 and 16 to Demonstrate How to Modify Pipe Specifications Using New CADWorx(R) DraftPro(TM) for Intelligent 2D Plant Design HOUSTON, TX--(Marketwire - Feb 3, 2012) - Intergraph has scheduled CADWorx DraftPro webinars on February 15 at 10:00 a.m. and February 16, 2012 at 7:00 p.m. CT that will cover how to get started with pipe specifications, line numbers, and layouts using this new AutoCAD®-based intelligent 2D plant design and layout solution. The webinar will show how the built-in editor allows you to easily modify the supplied piping specifications to match your exact needs, saving time and providing accura...
>The Medicines Company to Announce Fourth Quarter and Full Year 2011 Financial Results on Wednesday, February 22, 2012 Conference Call to Be Held at 8:30 a.m. Eastern Time
>Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs STOCKHOLM, SWEDEN--(Marketwire - Feb 6, 2012) - Sobi and Biogen Idec have agreed to disclose further details on their agreement regarding development and commercialization of long-lasting recombinant factor VIII and factor IX hemophilia programs, which was restructured in February 2010. Under the new agreement, Biogen Idec assumed full development responsibilities and costs, as well as manufacturing rights. In addition, the cross-royalty rates were reduced and commercial rights for certain...
>Pyng Medical Corp. Announces Bridge Loan VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 3, 2012) - Pyng Medical Corp. (TSX VENTURE:PYT) ("Pyng" or the "Company") today announced a loan (the "Loan") in the amount of US$220,000 from its largest shareholder Excelera Corporation ("Excelera"). The Loan carries interest at 11% per annum, is unsecured, and does not include an equity component. The total principal and interest is due on April 12, 2012.
>Elderly Alerts, Leader in Medical Alert Systems, Educates the Elderly Community via Twitter Through Social Media, Elderly Alerts Educates on the Importance of Having Medical Alert Alarms at Home
>Intergraph(R) Webinars on February 15 and 16 to Demonstrate How to Modify Pipe Specifications Using New CADWorx(R) DraftPro(TM) for Intelligent 2D Plant Design HOUSTON, TX--(Marketwire - Feb 3, 2012) - Intergraph has scheduled CADWorx DraftPro webinars on February 15 at 10:00 a.m. and February 16, 2012 at 7:00 p.m. CT that will cover how to get started with pipe specifications, line numbers, and layouts using this new AutoCAD®-based intelligent 2D plant design and layout solution. The webinar will show how the built-in editor allows you to easily modify the supplied piping specifications to match your exact needs, saving time and providing accura...
>The Medicines Company to Announce Fourth Quarter and Full Year 2011 Financial Results on Wednesday, February 22, 2012 Conference Call to Be Held at 8:30 a.m. Eastern Time
MassBio News
>NUCLEA BIOTECHNOLOGIES ANNOUNCES $3.4 MILLION IN CAPITAL COMMITMENTSPittsfield, MA ? Nuclea Biotechnologies, Inc. today announced that the Company has closed on an additional $3.4 million in funding and committed financing. The financing includes $1.4 million in additional cash and $2.0 million in future commitments through March 31, 2012. This transaction finalizes the Company?s Series B Convertible Preferred Stock offering which amounted to $9.8 million. The Pittsfield-based company is focused on the development, clinical validation and commercialization...
>Annual Policy Breakfast Makes Headlines on Healthcare ReformMassBio garnered headlines last week as discussion at the annual Policy Leadership Breakfast centered on one of state government?s hottest topics? the rising costs of healthcare, and how government intends to get involved. More than 250 MassBio members joined dozens of legislators and staff to discuss the potential impacts of healthcare reform implementation both nationwide and here in Massachusetts. A panel discussion focused on the future of payment reform in the Commonwealth. Panelists ...
>MassBio Introduces the Leading Edge AwardHonor recognizes efforts to improve Massachusetts? competitiveness January 24, 2012 (Cambridge, MA) ? This year, in order to recognize companies working to shape Massachusetts as the ideal setting for life sciences companies, the Economic Development Advisory Group (EDAG) at MassBio has established the Leading Edge Award. This award will annually recognize significant contributions made by individuals and organizations to further Massachusetts as a biotechnology and life sciences hub. Ma...
>MassBio Policy Update - SBIR Reauthorization On December 31, 2011, President Obama signed the National Defense Authorization Act for Fiscal Year 2012 (the Act), which included provisions reauthorizing the Small Business Innovation Research (SBIR) for an additional six years and expanding the eligibility of venture-backed companies to receive SBIR grants (the Reauthorization). The SBIR program is an award system for funding small businesses that propose and perform research and development that meet criteria specified by agenc...
>451 Marketing & Freeman to Create Massachusetts Pavilion at 2012 BIO International ConventionFirms to design & build innovative exhibit for June industry show January 18, 2012 (Cambridge, MA)? MassBio today announced that 451 Marketing and Freeman have been hired to design and build the Massachusetts Pavilion at the 2012 BIO International Convention in Boston. MassBio is coordinating the 7,700-square-foot Pavilion at the convention, which showcases and connects the people, companies and innovations that help to fulfill the promise of biotechnology through healing, fueling, and feed...
>NUCLEA BIOTECHNOLOGIES ANNOUNCES $3.4 MILLION IN CAPITAL COMMITMENTSPittsfield, MA ? Nuclea Biotechnologies, Inc. today announced that the Company has closed on an additional $3.4 million in funding and committed financing. The financing includes $1.4 million in additional cash and $2.0 million in future commitments through March 31, 2012. This transaction finalizes the Company?s Series B Convertible Preferred Stock offering which amounted to $9.8 million. The Pittsfield-based company is focused on the development, clinical validation and commercialization...
>Annual Policy Breakfast Makes Headlines on Healthcare ReformMassBio garnered headlines last week as discussion at the annual Policy Leadership Breakfast centered on one of state government?s hottest topics? the rising costs of healthcare, and how government intends to get involved. More than 250 MassBio members joined dozens of legislators and staff to discuss the potential impacts of healthcare reform implementation both nationwide and here in Massachusetts. A panel discussion focused on the future of payment reform in the Commonwealth. Panelists ...
>MassBio Introduces the Leading Edge AwardHonor recognizes efforts to improve Massachusetts? competitiveness January 24, 2012 (Cambridge, MA) ? This year, in order to recognize companies working to shape Massachusetts as the ideal setting for life sciences companies, the Economic Development Advisory Group (EDAG) at MassBio has established the Leading Edge Award. This award will annually recognize significant contributions made by individuals and organizations to further Massachusetts as a biotechnology and life sciences hub. Ma...
>MassBio Policy Update - SBIR Reauthorization On December 31, 2011, President Obama signed the National Defense Authorization Act for Fiscal Year 2012 (the Act), which included provisions reauthorizing the Small Business Innovation Research (SBIR) for an additional six years and expanding the eligibility of venture-backed companies to receive SBIR grants (the Reauthorization). The SBIR program is an award system for funding small businesses that propose and perform research and development that meet criteria specified by agenc...
>451 Marketing & Freeman to Create Massachusetts Pavilion at 2012 BIO International ConventionFirms to design & build innovative exhibit for June industry show January 18, 2012 (Cambridge, MA)? MassBio today announced that 451 Marketing and Freeman have been hired to design and build the Massachusetts Pavilion at the 2012 BIO International Convention in Boston. MassBio is coordinating the 7,700-square-foot Pavilion at the convention, which showcases and connects the people, companies and innovations that help to fulfill the promise of biotechnology through healing, fueling, and feed...
Medical Pharma - PR Newswire
>St. Jude Children's Research Hospital Celebrates 50 YearsTennessee Governor Proclaims February as St. Jude Month MEMPHIS, Tenn., Feb. 4, 2012 /PRNewswire-USNewswire/ -- In 1962, St. Jude Children's Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few...
>Faruqi & Faruqi, LLP Files Securities Class Action Suit Against China Medical Technologies, Inc. and Certain of Its ExecutivesNEW YORK, Feb. 3, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP today announced that it has filed a securities class action lawsuit against China Medical Technologies, Inc. ("China Medical" or the "Company") (NASDAQ: CMED) and certain of its senior executives. The action (No....
>Pharmaceutical and Medical Device Companies Shift Medical Education Focus into Emerging MarketsCHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- In the current environment, medical education groups are faced with the challenge of holding down costs while adding new programs and expanding into emerging markets. As a result, pharmaceutical and medical device leaders are beginning...
>Vita Needle Company Receives ISO 9001 and ISO 13485 CertificationsNEEDHAM, Mass., Feb. 3, 2012 /PRNewswire-iReach/ -- Vita Needle Company recently celebrated dual certifications of its Quality Management Systems to the latest general ISO 9001:2008 and medical device manufacturing standards ISO 13485:2003. In addition, the fifth generation...
>Unity Management Group Announces Additions to Executive Management Team, Acquisition, and Additional ContractsEAST HANOVER, N.J., Feb. 3, 2012 /PRNewswire/ -- Unity Management Group, Inc. (OTC: UYMG) (or "the Company") announced today Dr. Michael Levin has joined its wholly owned subsidiary Metropolitan Computing Corporation (or MCC) to manage product development, develop new business, and...
>St. Jude Children's Research Hospital Celebrates 50 YearsTennessee Governor Proclaims February as St. Jude Month MEMPHIS, Tenn., Feb. 4, 2012 /PRNewswire-USNewswire/ -- In 1962, St. Jude Children's Research Hospital opened its doors amid an emotionally charged debate regarding how to treat childhood cancer. At that time, few...
>Faruqi & Faruqi, LLP Files Securities Class Action Suit Against China Medical Technologies, Inc. and Certain of Its ExecutivesNEW YORK, Feb. 3, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP today announced that it has filed a securities class action lawsuit against China Medical Technologies, Inc. ("China Medical" or the "Company") (NASDAQ: CMED) and certain of its senior executives. The action (No....
>Pharmaceutical and Medical Device Companies Shift Medical Education Focus into Emerging MarketsCHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- In the current environment, medical education groups are faced with the challenge of holding down costs while adding new programs and expanding into emerging markets. As a result, pharmaceutical and medical device leaders are beginning...
>Vita Needle Company Receives ISO 9001 and ISO 13485 CertificationsNEEDHAM, Mass., Feb. 3, 2012 /PRNewswire-iReach/ -- Vita Needle Company recently celebrated dual certifications of its Quality Management Systems to the latest general ISO 9001:2008 and medical device manufacturing standards ISO 13485:2003. In addition, the fifth generation...
>Unity Management Group Announces Additions to Executive Management Team, Acquisition, and Additional ContractsEAST HANOVER, N.J., Feb. 3, 2012 /PRNewswire/ -- Unity Management Group, Inc. (OTC: UYMG) (or "the Company") announced today Dr. Michael Levin has joined its wholly owned subsidiary Metropolitan Computing Corporation (or MCC) to manage product development, develop new business, and...
National Center for Biotechnology Information
>GEO Series ReleasesNotifications of functional genomic studies released by the Gene Expression Omnibus (GEO) database.
>ClinVar News and AnnouncementsBrief Announcements highlighting recent changes and enhancements to ClinVar database.
>Behind The Headlines - Health News from NHS ChoicesBehind the Headlines is a constantly updated health news across a range of subjects. It provides an unbiased and evidence-based analysis of health stories that make the news. Published by UK NHS Choices.
>PubMed Health Featured ReviewsPubMed Health featured clinical effectiveness reviews
>SRA NewsBrief annoucements for new features and pipeline changes to the Sequence Read Archive.
>GEO Series ReleasesNotifications of functional genomic studies released by the Gene Expression Omnibus (GEO) database.
>ClinVar News and AnnouncementsBrief Announcements highlighting recent changes and enhancements to ClinVar database.
>Behind The Headlines - Health News from NHS ChoicesBehind the Headlines is a constantly updated health news across a range of subjects. It provides an unbiased and evidence-based analysis of health stories that make the news. Published by UK NHS Choices.
>PubMed Health Featured ReviewsPubMed Health featured clinical effectiveness reviews
>SRA NewsBrief annoucements for new features and pipeline changes to the Sequence Read Archive.
Nature Biotechnology
>Approval on a knife edgeIn spite of its modest performance in clinical trials, Benlysta may offer effective relief against lupus. But physicians are still working to identify the right patients. Michael Eisenstein reports.
>Bringing business risk into sharp focus
>The NIH's role in accelerating translational sciencesThe NIH's proposed initiatives in translational science deserve solid financial backing from legislators and vocal support from the biomedical community.
>Building stem-cell genomics in California and beyondBy devoting funding to whole-genome studies, such as epigenetic and copy-number variation in stem cells, research on new genomic technology, and standards for methodologies and data collection/sharing, CIRM can spur both basic and translational research.
>Foundation MedicineThe Cambridge, Massachusetts?based company plans to introduce next-generation gene sequencing into oncology practice and pathologists' laboratories.
>Approval on a knife edgeIn spite of its modest performance in clinical trials, Benlysta may offer effective relief against lupus. But physicians are still working to identify the right patients. Michael Eisenstein reports.
>Bringing business risk into sharp focus
>The NIH's role in accelerating translational sciencesThe NIH's proposed initiatives in translational science deserve solid financial backing from legislators and vocal support from the biomedical community.
>Building stem-cell genomics in California and beyondBy devoting funding to whole-genome studies, such as epigenetic and copy-number variation in stem cells, research on new genomic technology, and standards for methodologies and data collection/sharing, CIRM can spur both basic and translational research.
>Foundation MedicineThe Cambridge, Massachusetts?based company plans to introduce next-generation gene sequencing into oncology practice and pathologists' laboratories.
New York Times- Biotechnology
>Cancer Center, in Suit, Claims Ex-Official Took ResearchThe president of Memorial Sloan-Kettering Cancer Center, Dr. Craig B. Thompson, is in a billion-dollar dispute with his former workplace over accusations that he walked away with research.
>Life Sciences Development Rebounds in Central New JerseyWith its concentration of pharmaceutical giants and academic powerhouses, the region could be a major center for life sciences businesses, developers say.
>Amgen and Watson to Work Together on Generic DrugsThe two companies will develop and sell cheaper versions of several biologic cancer drugs.
>A Genome DelugeDNA sequencing is becoming faster and cheaper, outrunning the ability to store, transmit and analyze the data; this could delay the day when DNA sequencing is routinely used in medicine. Photo
>Drew Endy: Better Computing for the Things We Care About MostFrom scheduling conference rooms to rooting out incipient tumors, computers that can go to the information that we care greatly about
>Cancer Center, in Suit, Claims Ex-Official Took ResearchThe president of Memorial Sloan-Kettering Cancer Center, Dr. Craig B. Thompson, is in a billion-dollar dispute with his former workplace over accusations that he walked away with research.
>Life Sciences Development Rebounds in Central New JerseyWith its concentration of pharmaceutical giants and academic powerhouses, the region could be a major center for life sciences businesses, developers say.
>Amgen and Watson to Work Together on Generic DrugsThe two companies will develop and sell cheaper versions of several biologic cancer drugs.
>A Genome DelugeDNA sequencing is becoming faster and cheaper, outrunning the ability to store, transmit and analyze the data; this could delay the day when DNA sequencing is routinely used in medicine. Photo
>Drew Endy: Better Computing for the Things We Care About MostFrom scheduling conference rooms to rooting out incipient tumors, computers that can go to the information that we care greatly about
New York Times- Pharmaceuticals
>Children’s A.D.D. Drugs Don’t Work Long-TermMillions of children take drugs to help them pay attention — but do they really help?
>Army Studies Workout Supplements After 2 DeathsThe military has removed dietary supplements containing the ingredient dimethylamylamine from stores on its bases, though the products are widely available elsewhere in the country.
>Pfizer and Eli Lilly, Squeezed by Generics, Top ForecastsThe fourth quarter was the first without patent protection for both Pfizer and its blockbuster cholesterol drug Lipitor, and Lilly, which markets Zyprexa, long its biggest product.
>F.D.A. Approves Cystic Fibrosis DrugThe federal agency called it a “breakthrough therapy” because current therapies treat only the symptoms of the genetic disease.
>F.D.A. Approves Drug for an Advanced Skin CancerThe drug, Erivedge, made by Genentech, was approved for adults with basal cell carcinoma that has spread elsewhere in the body or those who are not candidates for surgery or radiation.
>Children’s A.D.D. Drugs Don’t Work Long-TermMillions of children take drugs to help them pay attention — but do they really help?
>Army Studies Workout Supplements After 2 DeathsThe military has removed dietary supplements containing the ingredient dimethylamylamine from stores on its bases, though the products are widely available elsewhere in the country.
>Pfizer and Eli Lilly, Squeezed by Generics, Top ForecastsThe fourth quarter was the first without patent protection for both Pfizer and its blockbuster cholesterol drug Lipitor, and Lilly, which markets Zyprexa, long its biggest product.
>F.D.A. Approves Cystic Fibrosis DrugThe federal agency called it a “breakthrough therapy” because current therapies treat only the symptoms of the genetic disease.
>F.D.A. Approves Drug for an Advanced Skin CancerThe drug, Erivedge, made by Genentech, was approved for adults with basal cell carcinoma that has spread elsewhere in the body or those who are not candidates for surgery or radiation.
OnBioVC
>IntegenX, Inc.: Series C $40MIntegenX (Pleasanton, CA) a commercial-stage device company focused on sample preparation for next generation sequencing, closed a $40M Series C financing. Participants include Essex Woodlands, Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, Rona Holdings, Samsung Ventures and In-Q-Tel.
>Verona Pharma, Ltd.: Series A $11.5MVerona Pharma (United Kingdom) a clinical-stage biotechnology company focused on chronic respiratory diseases and inflammation for asthma, COPD, cough, and rhinitis, closed a $11.5M Series A financing. Participants include Henderson Global Investors.
>Aratana Therapeutics, Inc.: Series B $15.5MAratana Therapeutics (Kansas City, KS) a clinical-stage animal health company focused on pain, cancer, inflammation, cachexia and frailty, closed a $15.5M Series B financing. Participants include Ewing Marion Kauffman Foundation, MPM Capital, Cultivian Ventures and Avalon Ventures.
>ImmusanT, Inc.: Series A $20MImmusanT (Cambridge, MA) a clinical-stage biopharmaceutical company focused on a peptide-based vaccine for celiac disease, closed a $20M Series A financing. Participants include Vatera Healthcare Partners.
>Sotera Wireless, Inc.: Series D $12.2MSotera Wireless (San Diego, CA) a clinical-stage medical device company focused on vital signs monitoring, closed a $12.2M Series D financing. Participants include EDBI, Cerner Capital, Sanderling Ventures, Qualcomm Ventures, Intel Capital and West Health Investment Fund.
>IntegenX, Inc.: Series C $40MIntegenX (Pleasanton, CA) a commercial-stage device company focused on sample preparation for next generation sequencing, closed a $40M Series C financing. Participants include Essex Woodlands, Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, Rona Holdings, Samsung Ventures and In-Q-Tel.
>Verona Pharma, Ltd.: Series A $11.5MVerona Pharma (United Kingdom) a clinical-stage biotechnology company focused on chronic respiratory diseases and inflammation for asthma, COPD, cough, and rhinitis, closed a $11.5M Series A financing. Participants include Henderson Global Investors.
>Aratana Therapeutics, Inc.: Series B $15.5MAratana Therapeutics (Kansas City, KS) a clinical-stage animal health company focused on pain, cancer, inflammation, cachexia and frailty, closed a $15.5M Series B financing. Participants include Ewing Marion Kauffman Foundation, MPM Capital, Cultivian Ventures and Avalon Ventures.
>ImmusanT, Inc.: Series A $20MImmusanT (Cambridge, MA) a clinical-stage biopharmaceutical company focused on a peptide-based vaccine for celiac disease, closed a $20M Series A financing. Participants include Vatera Healthcare Partners.
>Sotera Wireless, Inc.: Series D $12.2MSotera Wireless (San Diego, CA) a clinical-stage medical device company focused on vital signs monitoring, closed a $12.2M Series D financing. Participants include EDBI, Cerner Capital, Sanderling Ventures, Qualcomm Ventures, Intel Capital and West Health Investment Fund.
Outsourcing-Pharma
>An experienced CMO is key to successful biologics development says Cobra BiologicsDetailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
>Parexel discusses transdermal drug delivery techsElectroporation is the wave of the future for transdermal drug delivery, according to Parexel?s Ravi Harapanhalli.
>Sponsors and CROs differ on perception of service quality, says the Avoca GroupSponsor and CRO perceptions of the quality of outsourced service provision differ markedly according to a study by consulting and survey research organisation, the Avoca Group.
>Recipharm CEO talks CMO sector recovery and Asian plansThe global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
>Covance adding mass spec for biosimilarsCovance is adding mass spectrometry and other capabilities to meet growing demand for biosimilar comparability services.
>An experienced CMO is key to successful biologics development says Cobra BiologicsDetailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
>Parexel discusses transdermal drug delivery techsElectroporation is the wave of the future for transdermal drug delivery, according to Parexel?s Ravi Harapanhalli.
>Sponsors and CROs differ on perception of service quality, says the Avoca GroupSponsor and CRO perceptions of the quality of outsourced service provision differ markedly according to a study by consulting and survey research organisation, the Avoca Group.
>Recipharm CEO talks CMO sector recovery and Asian plansThe global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
>Covance adding mass spec for biosimilarsCovance is adding mass spectrometry and other capabilities to meet growing demand for biosimilar comparability services.
Pharma News - Business Wire
>Celgene Executive Dr Rajesh Chopra Joins the Board of e-TherapeuticsOXFORD & NEWCASTLE, England--(BUSINESS WIRE)--Drug discovery and development company e-Therapeutics plc (AIM: ETX) announces that Dr Rajesh Chopra has joined the Company?s Board as a Non-Executive Director. A clinician and scientist by training, Dr Chopra has since 2009 been Vice President of Translational and Early Drug Development at Celgene Corporation. He leads a group of around 100 people working to integrate drug discovery and clinical development at Celgene sites in San Diego and San F...
>Gilead Sciences maakt financiële resultaten vierde kwartaal en gehele jaar 2011 bekendFOSTER CITY, Californië (VS)--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) maakte vandaag de resultaten bekend van hun activiteiten voor het vierde kwartaal en gehele jaar 2011. De totale opbrengsten voor het vierde kwartaal 2011 steeg met 10 procent tot $2,20 miljard, vergeleken met $2,00 miljard voor het vierde kwartaal 2010. De netto-inkomsten voor het vierde kwartaal van 2011 waren $665,1 miljoen, of $0,87 per verwaterd aandeel, vergeleken met $629,4 miljoen, of $0,76 per verwater...
>Gilead Sciences anuncia resultados cuarto trimestre y ejercicio completo 2011FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado hoy los resultados de sus operaciones para el cuarto trimestre y el ejercicio completo 2011. Los ingresos brutos totales para el cuarto trimestre de 2011 se elevaron a $2.200 millones, un aumento del 10% en comparación con los ingresos brutos totales de $2.000 millones del mismo trimestre de 2010. Los ingresos netos para el cuarto trimestre de 2011 alcanzaron los $665,1 millones, o $0,87 por acción diluida...
>Gilead Sciences gibt Finanzergebnisse für viertes Quartal und Gesamtjahr 2011 bekanntFOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (NASDAQ: GILD) hat heute seine Betriebsergebnisse für das vierte Quartal und das Gesamtjahr 2011 bekannt gegeben. Der Gesamtumsatz im vierten Quartal 2011 stieg um 10 Prozent auf 2,20 Milliarden US-Dollar gegenüber den 2,00 Milliarden US-Dollar im vierten Quartal 2010. Der Nettogewinn im vierten Quartal 2011 betrug 665,1 Millionen US-Dollar beziehungsweise 0,87 US-Dollar je verwässerte Aktie, dies gegenüber...
>Gilead Sciences annonce ses résultats financiers pour le quatrième trimestre et l?exercice 2011FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd?hui ses résultats d?exploitation pour le quatrième trimestre et l?exercice 2011. Le chiffre d?affaires total pour le quatrième trimestre 2011 a progressé de 10 % à 2,20 milliards USD, de 2,00 milliards USD au quatrième trimestre 2010. Le résultat net au quatrième trimestre 2011 a atteint 665,1 millions USD, soit 0,87 dollar par action diluée, comparé à 629,4 millions USD, soit 0,76 dollar par act...
>Celgene Executive Dr Rajesh Chopra Joins the Board of e-TherapeuticsOXFORD & NEWCASTLE, England--(BUSINESS WIRE)--Drug discovery and development company e-Therapeutics plc (AIM: ETX) announces that Dr Rajesh Chopra has joined the Company?s Board as a Non-Executive Director. A clinician and scientist by training, Dr Chopra has since 2009 been Vice President of Translational and Early Drug Development at Celgene Corporation. He leads a group of around 100 people working to integrate drug discovery and clinical development at Celgene sites in San Diego and San F...
>Gilead Sciences maakt financiële resultaten vierde kwartaal en gehele jaar 2011 bekendFOSTER CITY, Californië (VS)--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) maakte vandaag de resultaten bekend van hun activiteiten voor het vierde kwartaal en gehele jaar 2011. De totale opbrengsten voor het vierde kwartaal 2011 steeg met 10 procent tot $2,20 miljard, vergeleken met $2,00 miljard voor het vierde kwartaal 2010. De netto-inkomsten voor het vierde kwartaal van 2011 waren $665,1 miljoen, of $0,87 per verwaterd aandeel, vergeleken met $629,4 miljoen, of $0,76 per verwater...
>Gilead Sciences anuncia resultados cuarto trimestre y ejercicio completo 2011FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado hoy los resultados de sus operaciones para el cuarto trimestre y el ejercicio completo 2011. Los ingresos brutos totales para el cuarto trimestre de 2011 se elevaron a $2.200 millones, un aumento del 10% en comparación con los ingresos brutos totales de $2.000 millones del mismo trimestre de 2010. Los ingresos netos para el cuarto trimestre de 2011 alcanzaron los $665,1 millones, o $0,87 por acción diluida...
>Gilead Sciences gibt Finanzergebnisse für viertes Quartal und Gesamtjahr 2011 bekanntFOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (NASDAQ: GILD) hat heute seine Betriebsergebnisse für das vierte Quartal und das Gesamtjahr 2011 bekannt gegeben. Der Gesamtumsatz im vierten Quartal 2011 stieg um 10 Prozent auf 2,20 Milliarden US-Dollar gegenüber den 2,00 Milliarden US-Dollar im vierten Quartal 2010. Der Nettogewinn im vierten Quartal 2011 betrug 665,1 Millionen US-Dollar beziehungsweise 0,87 US-Dollar je verwässerte Aktie, dies gegenüber...
>Gilead Sciences annonce ses résultats financiers pour le quatrième trimestre et l?exercice 2011FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd?hui ses résultats d?exploitation pour le quatrième trimestre et l?exercice 2011. Le chiffre d?affaires total pour le quatrième trimestre 2011 a progressé de 10 % à 2,20 milliards USD, de 2,00 milliards USD au quatrième trimestre 2010. Le résultat net au quatrième trimestre 2011 a atteint 665,1 millions USD, soit 0,87 dollar par action diluée, comparé à 629,4 millions USD, soit 0,76 dollar par act...
Pharma News - PharmiWeb
>MSA Schedules Fourth Quarter Earnings WebcastMSA Schedules Fourth Quarter Earnings WebcastPR NewswirePITTSBURGH, Feb. 3, 2012PITTSBURGH, Feb. 3, 2012 /PRNewswire/ -- MSA (N...MSA
>AXESS gives TOPRA Regulatory Affairs MSc lectureAXESS gives TOPRA Regulatory Affairs MSc lecturePaul Foster, Talent Acquisition Manager for AXESS, is passing on his expertise ...AXESS
>Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical TrialsMolecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials...Molecular Profiles
>Michael Kaufmann of Cardinal Health Named as the Healthcare Businesswomen's Association's 2012 Honorable MentorMichael Kaufmann of Cardinal Health Named as the Healthcare Businesswomen's Association's 2012 Honorable MentorPR New...HEALTHCARE BUSINESSWOMEN'S ASSOCIATION
>Evergreen Awarded Distinguished Hospital for Clinical Excellence for the Fourth Consecutive YearEvergreen Awarded Distinguished Hospital for Clinical Excellence for the Fourth Consecutive YearPR NewswireKIRKLAND, Wash., Feb...FIRMANI AND ASSOCIATES
>MSA Schedules Fourth Quarter Earnings WebcastMSA Schedules Fourth Quarter Earnings WebcastPR NewswirePITTSBURGH, Feb. 3, 2012PITTSBURGH, Feb. 3, 2012 /PRNewswire/ -- MSA (N...MSA
>AXESS gives TOPRA Regulatory Affairs MSc lectureAXESS gives TOPRA Regulatory Affairs MSc lecturePaul Foster, Talent Acquisition Manager for AXESS, is passing on his expertise ...AXESS
>Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical TrialsMolecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials...Molecular Profiles
>Michael Kaufmann of Cardinal Health Named as the Healthcare Businesswomen's Association's 2012 Honorable MentorMichael Kaufmann of Cardinal Health Named as the Healthcare Businesswomen's Association's 2012 Honorable MentorPR New...HEALTHCARE BUSINESSWOMEN'S ASSOCIATION
>Evergreen Awarded Distinguished Hospital for Clinical Excellence for the Fourth Consecutive YearEvergreen Awarded Distinguished Hospital for Clinical Excellence for the Fourth Consecutive YearPR NewswireKIRKLAND, Wash., Feb...FIRMANI AND ASSOCIATES
Pharma News - PR Newswire
>Neue Studien zeigen, dass der Verzehr von Obst wichtiger für die männliche Attraktivität ist als MaskulinitätCAMBRIDGE, England, February 6, 2012 /PRNewswire/ -- Neuesten Forschungsergebnissen zufolge hat der Verzehr von dunkelfarbenem und frischem Obst, wie Pflaumen, Pfirsiche und Nektarinen, mehr Einfluss darauf, wie attraktiv ein Mann erscheint als seine Maskulinit? Dr. Ian Stephen...
>TPI to Host Second Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, February 14, 2012 at 8:30 a.m. ETCHENGDU, China, Feb. 5, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active...
>Cardinal Health Statement Regarding Temporary Restraining Order to Avoid Disruption in Controlled Medicine Shipments From FloridaDUBLIN, Ohio, Feb. 3, 2012 /PRNewswire/ -- Today Cardinal Health was granted a temporary restraining order against the Drug Enforcement Administration's (DEA) immediate suspension order of its Lakeland, Fla. DEA registration. U.S. District Court for the District of Columbia...
>Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities AttorneysDALLAS, Feb. 3, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating whether certain officers and directors of Micromet, Inc. (NASDAQ: MITI) violated shareholder protection laws by agreeing to a tender offer for $11.00 per share to Amgen. Concerned Micromet...
>Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPIRIDGEFIELD, Conn., Feb. 3, 2012 /PRNewswire/ -- Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor...
>Neue Studien zeigen, dass der Verzehr von Obst wichtiger für die männliche Attraktivität ist als MaskulinitätCAMBRIDGE, England, February 6, 2012 /PRNewswire/ -- Neuesten Forschungsergebnissen zufolge hat der Verzehr von dunkelfarbenem und frischem Obst, wie Pflaumen, Pfirsiche und Nektarinen, mehr Einfluss darauf, wie attraktiv ein Mann erscheint als seine Maskulinit? Dr. Ian Stephen...
>TPI to Host Second Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, February 14, 2012 at 8:30 a.m. ETCHENGDU, China, Feb. 5, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active...
>Cardinal Health Statement Regarding Temporary Restraining Order to Avoid Disruption in Controlled Medicine Shipments From FloridaDUBLIN, Ohio, Feb. 3, 2012 /PRNewswire/ -- Today Cardinal Health was granted a temporary restraining order against the Drug Enforcement Administration's (DEA) immediate suspension order of its Lakeland, Fla. DEA registration. U.S. District Court for the District of Columbia...
>Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities AttorneysDALLAS, Feb. 3, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating whether certain officers and directors of Micromet, Inc. (NASDAQ: MITI) violated shareholder protection laws by agreeing to a tender offer for $11.00 per share to Amgen. Concerned Micromet...
>Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPIRIDGEFIELD, Conn., Feb. 3, 2012 /PRNewswire/ -- Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor...
Pharmaceutical - Moreover
>: Pharmaceuticals look to cure pipeline concernsPharmaceutical companies are considered to be one of the more defensive sectors, with high margins, significant non-cyclical cashflows and relatively low levels of leverage all helping contribute to good performance in
>Drug firms sign up to new tropical disease fightKey players in the pharmaceutical industry pledged on Monday to donate 14 billion drug treatments as part of a new, global push to eradicate tropical diseases
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are NoCannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient
>Micro Labs attracts private equity and pharma interest: VCCircleAnother high value deal in India?s pharmaceutical sector may be in the pipeline, as Bangalore?s Micro Labs attracts the interest of major drug companies Teva and Pfizer, as well as private equity houses, people with knowledge
>Novartis net dips by 5.3% to Rs.38 crore in Q3worked out to Rs.11.99 as against Rs.12.67 in the last period. The company's pharmaceutical sales increased to Rs.142.20 crore from Rs.124.9 crore, registering a growth of 13.9 per cent during the quarter under review. Its generic division sales increased
>: Pharmaceuticals look to cure pipeline concernsPharmaceutical companies are considered to be one of the more defensive sectors, with high margins, significant non-cyclical cashflows and relatively low levels of leverage all helping contribute to good performance in
>Drug firms sign up to new tropical disease fightKey players in the pharmaceutical industry pledged on Monday to donate 14 billion drug treatments as part of a new, global push to eradicate tropical diseases
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are NoCannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient
>Micro Labs attracts private equity and pharma interest: VCCircleAnother high value deal in India?s pharmaceutical sector may be in the pipeline, as Bangalore?s Micro Labs attracts the interest of major drug companies Teva and Pfizer, as well as private equity houses, people with knowledge
>Novartis net dips by 5.3% to Rs.38 crore in Q3worked out to Rs.11.99 as against Rs.12.67 in the last period. The company's pharmaceutical sales increased to Rs.142.20 crore from Rs.124.9 crore, registering a growth of 13.9 per cent during the quarter under review. Its generic division sales increased
PR Leap - Biotech
>Abcam Biochemicals is launched; the new name for Ascent Scientific productsAbcam Biochemicals is the new name for the Ascent Scientific range of exceptional quality, high performance biochemicals.
>AL-TAR Services, Inc. Adds Thermo-Scientific Product Line to its Online Lab Equipment Store AL-TAR Services, Inc. announces new sales channel partnership with Thermo-Scientific laboratory equipment.
>Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of NewcastleAscent Scientific together with Children's Medical Research Institute and The University of Newcastle today announced that they have entered into a license, supply and distribution agreement for the highly potent dynamin inhibitor Dyngo-4a™. This novel compound joins a range of dynamin inhibitors that can be used for investigating cellular processes such as endocytosis. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
>AL-TAR Services, Inc. Names Robert Nugent Director of Business Development AL-TAR Services, Inc. welcomes Robert Nugent as new Director of Business Development for AL-TAR's team of laboratory equipment calibration and repair experts.
>Ascent Scientific licenses novel clathrin inhibitors from Freie Universität Berlin, University of Newcastle and Children's Medical Research InstituteAscent Scientific, together with Freie Universität Berlin, The University of Newcastle and Children's Medical Research Institute today announced that they have entered into an exclusive licence, supply and distribution agreement for the clathrin inhibitors Pitstop 1™ and Pitstop 2™ for research. These novel compounds are the first rationally designed inhibitors of clathrin, and represent important tools for investigating essential cellular processes such as endocytosis.
>Abcam Biochemicals is launched; the new name for Ascent Scientific productsAbcam Biochemicals is the new name for the Ascent Scientific range of exceptional quality, high performance biochemicals.
>AL-TAR Services, Inc. Adds Thermo-Scientific Product Line to its Online Lab Equipment Store AL-TAR Services, Inc. announces new sales channel partnership with Thermo-Scientific laboratory equipment.
>Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of NewcastleAscent Scientific together with Children's Medical Research Institute and The University of Newcastle today announced that they have entered into a license, supply and distribution agreement for the highly potent dynamin inhibitor Dyngo-4a™. This novel compound joins a range of dynamin inhibitors that can be used for investigating cellular processes such as endocytosis. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
>AL-TAR Services, Inc. Names Robert Nugent Director of Business Development AL-TAR Services, Inc. welcomes Robert Nugent as new Director of Business Development for AL-TAR's team of laboratory equipment calibration and repair experts.
>Ascent Scientific licenses novel clathrin inhibitors from Freie Universität Berlin, University of Newcastle and Children's Medical Research InstituteAscent Scientific, together with Freie Universität Berlin, The University of Newcastle and Children's Medical Research Institute today announced that they have entered into an exclusive licence, supply and distribution agreement for the clathrin inhibitors Pitstop 1™ and Pitstop 2™ for research. These novel compounds are the first rationally designed inhibitors of clathrin, and represent important tools for investigating essential cellular processes such as endocytosis.
PRWeb - Biotechnology
>Oryzon Nominates Bispecific LSD1/MAOB Inhibitor as Drug Candidate to... ORYZON announced today that it is entering preclinical development with its first drug candidate, a first-in-class bispecific inhibitor for the treatment of Huntington disease (HD). These inhibitors...(PRWeb February 05, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9165166.htm
>Neuroscientists Join Max Planck Florida Institute as Leaders of Two... Neuroscientists Hyungbae Kwon, PhD and Hiroki Taniguchi, PhD will join Max Planck Florida Institute as research group leaders. MPFI will now have eight research groups, each dedicated to...(PRWeb February 04, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9162575.htm
>Westbridge Announces Blossom Protect has been Approved by EPA as a... Westbridge Agricultural Products announces that the EPA has approved Blossom Protect as a biopesticide for controlling fire blight in apple and pear orchards in the United States. Fire blight causes...(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9163257.htm
>Anaerobic Digestion Says: Waste to Energy and Biomass set to be the... Anaerobic Digestion Says: According to Bloomberg New Energy Finance, ?Investment in biomass and waste-to-energy is projected to increase from $14bn in 2010 to $80bn by 2020?. Among the greatest...(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9158142.htm
>invivodata Co-Founder Dr. Saul Shiffman Recognized by Carnegie Science... Shiffman Recognized for Groundbreaking Research in Patient Data Collection(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9161843.htm
>Oryzon Nominates Bispecific LSD1/MAOB Inhibitor as Drug Candidate to... ORYZON announced today that it is entering preclinical development with its first drug candidate, a first-in-class bispecific inhibitor for the treatment of Huntington disease (HD). These inhibitors...(PRWeb February 05, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9165166.htm
>Neuroscientists Join Max Planck Florida Institute as Leaders of Two... Neuroscientists Hyungbae Kwon, PhD and Hiroki Taniguchi, PhD will join Max Planck Florida Institute as research group leaders. MPFI will now have eight research groups, each dedicated to...(PRWeb February 04, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9162575.htm
>Westbridge Announces Blossom Protect has been Approved by EPA as a... Westbridge Agricultural Products announces that the EPA has approved Blossom Protect as a biopesticide for controlling fire blight in apple and pear orchards in the United States. Fire blight causes...(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9163257.htm
>Anaerobic Digestion Says: Waste to Energy and Biomass set to be the... Anaerobic Digestion Says: According to Bloomberg New Energy Finance, ?Investment in biomass and waste-to-energy is projected to increase from $14bn in 2010 to $80bn by 2020?. Among the greatest...(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9158142.htm
>invivodata Co-Founder Dr. Saul Shiffman Recognized by Carnegie Science... Shiffman Recognized for Groundbreaking Research in Patient Data Collection(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9161843.htm
PRWeb - Pharmaceuticals
>Bill Would Block FDA 510(k) Approval For Medical Devices Associated... Bernstein Liebhard reports on a newly introduced bill that would prevent medical device manufacturers from using the 510(k) process to receive FDA approval if they are predicated on previously...(PRWeb February 05, 2012)Read the full story at http://www.prweb.com/releases/vaginal-mesh-lawsuit/consumer-injury-lawyers/prweb9167102.htm
>Gemba Academy Expands Global Server Network Delivering Online Lean... Gemba Academy has expanded its server network to twenty-four locations around the globe. This allows for the efficient delivery of high definition on-demand lean enterprise and lean manufacturing...(PRWeb February 05, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9168250.htm
>Vet Cooperative Will Improve Independent Animal Hospital Sales,... Animal Hospitals have a purchasing disadvantage compared to online and local drugstores, as well as the big chain pet stores. This leads to lower profits for the veterinarian and high prices for...(PRWeb February 04, 2012)Read the full story at http://www.prweb.com/releases/tvc/02-03-12/prweb9165801.htm
>The 4th Annual HTAA Healthy Trucking Summit will be the Trucking... The Healthy Trucking Association of America (HTAA) is proud to announce the details of the 2012 HTAA Healthy Trucking Summit in Atlanta, Georgia. The HTAA Healthy Trucking Summit is the trucking...(PRWeb February 04, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9159074.htm
>Patient Conversation Media, Inc. Network Reaches 10 Million Unique... Patient Conversation's eHealth 3.0 patient education integrates news and videos(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9162130.htm
>Bill Would Block FDA 510(k) Approval For Medical Devices Associated... Bernstein Liebhard reports on a newly introduced bill that would prevent medical device manufacturers from using the 510(k) process to receive FDA approval if they are predicated on previously...(PRWeb February 05, 2012)Read the full story at http://www.prweb.com/releases/vaginal-mesh-lawsuit/consumer-injury-lawyers/prweb9167102.htm
>Gemba Academy Expands Global Server Network Delivering Online Lean... Gemba Academy has expanded its server network to twenty-four locations around the globe. This allows for the efficient delivery of high definition on-demand lean enterprise and lean manufacturing...(PRWeb February 05, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9168250.htm
>Vet Cooperative Will Improve Independent Animal Hospital Sales,... Animal Hospitals have a purchasing disadvantage compared to online and local drugstores, as well as the big chain pet stores. This leads to lower profits for the veterinarian and high prices for...(PRWeb February 04, 2012)Read the full story at http://www.prweb.com/releases/tvc/02-03-12/prweb9165801.htm
>The 4th Annual HTAA Healthy Trucking Summit will be the Trucking... The Healthy Trucking Association of America (HTAA) is proud to announce the details of the 2012 HTAA Healthy Trucking Summit in Atlanta, Georgia. The HTAA Healthy Trucking Summit is the trucking...(PRWeb February 04, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9159074.htm
>Patient Conversation Media, Inc. Network Reaches 10 Million Unique... Patient Conversation's eHealth 3.0 patient education integrates news and videos(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9162130.htm
Scientific American
>Human Waste-Powered Robots May Be Future of MachinesToday's robots that fly, jump or roll around must refuel or recharge as does any gadget that runs out of energy. Tomorrow's new generation of self-sustaining robots might keep going nearly forever by grazing on dead insects, rotting plant matter or even human waste. [More]
>Russian Scientists Poised to be First to Reach Ice-Buried Antarctic LakeAt a tiny outpost in the middle of Antarctica, Russian scientists are poised to become the first humans to reach a massive liquid lake that has been cut off from the sunlit world for millennia, and may house uniquely adapted life forms that are new to science. [More]
>Is It Ethical to Own an iPhone?Recent media reports and ongoing protests over the reportedly abhorrent working conditions at factories where Apple's iPhones are produced have left socially conscious Americans with a dilemma: Is it ethical to own an iPhone? [More]
>Virtual Reality Contact Lenses Could Be Available by 2014Contact lenses that help enhance normal vision with megapixel 3D panoramic images are being designed by scientists using military funding. [More]
>Temperatures--Not Acid--Could Cook Coral to DeathOne of the biggest natural tragedies of recent years is the deterioration of Australia's Great Barrier Reef , a vast structure of coral off the continent's east coast that supports a profusion of wildlife. In addition to overfishing and nutrient pollution, the world's largest natural structure has suffered from rising ocean temperatures. But, perhaps less well known, Australia's west coast has some massive reefs of its own, offshore in the southeastern Indian Ocean. Massive stony corals of t...
>Human Waste-Powered Robots May Be Future of MachinesToday's robots that fly, jump or roll around must refuel or recharge as does any gadget that runs out of energy. Tomorrow's new generation of self-sustaining robots might keep going nearly forever by grazing on dead insects, rotting plant matter or even human waste. [More]
>Russian Scientists Poised to be First to Reach Ice-Buried Antarctic LakeAt a tiny outpost in the middle of Antarctica, Russian scientists are poised to become the first humans to reach a massive liquid lake that has been cut off from the sunlit world for millennia, and may house uniquely adapted life forms that are new to science. [More]
>Is It Ethical to Own an iPhone?Recent media reports and ongoing protests over the reportedly abhorrent working conditions at factories where Apple's iPhones are produced have left socially conscious Americans with a dilemma: Is it ethical to own an iPhone? [More]
>Virtual Reality Contact Lenses Could Be Available by 2014Contact lenses that help enhance normal vision with megapixel 3D panoramic images are being designed by scientists using military funding. [More]
>Temperatures--Not Acid--Could Cook Coral to DeathOne of the biggest natural tragedies of recent years is the deterioration of Australia's Great Barrier Reef , a vast structure of coral off the continent's east coast that supports a profusion of wildlife. In addition to overfishing and nutrient pollution, the world's largest natural structure has suffered from rising ocean temperatures. But, perhaps less well known, Australia's west coast has some massive reefs of its own, offshore in the southeastern Indian Ocean. Massive stony corals of t...
Sports - ESPN Basketball
>Miami earns school's first win at Duke after OT Reggie Johnson scored five of his career-high 27 points in overtime and Miami upset Duke (No. 5 ESPN/USA Today, No. 7 AP) 78-74 on Sunday.
>Green backs talk, leads Mich. St. past Michigan Draymond Green had 14 points and 16 rebounds to lead Michigan State to a 64-54 win over Michigan on Sunday, backing up his guarantee of a victory.
>Mizzou edges Kansas on Denmon's huge finish No. 4 Missouri 74, No. 8 Kansas 71
>Missouri pro athletes to aid tornado-torn Joplin Flanked by representatives from Missouri pro sports teams prior to the Kansas-Missouri basketball game, Gov. Jay Nixon launched an effort to build 35 houses in tornado-devastated Joplin.
>Indiana rolls, ends 5-game skid against Purdue Victor Oladipo scored a career-high 23 points to help No. 20 Indiana defeat Purdue 78-61 on Saturday night and break a five-game losing streak to its in-state rival.
>Miami earns school's first win at Duke after OT Reggie Johnson scored five of his career-high 27 points in overtime and Miami upset Duke (No. 5 ESPN/USA Today, No. 7 AP) 78-74 on Sunday.
>Green backs talk, leads Mich. St. past Michigan Draymond Green had 14 points and 16 rebounds to lead Michigan State to a 64-54 win over Michigan on Sunday, backing up his guarantee of a victory.
>Mizzou edges Kansas on Denmon's huge finish No. 4 Missouri 74, No. 8 Kansas 71
>Missouri pro athletes to aid tornado-torn Joplin Flanked by representatives from Missouri pro sports teams prior to the Kansas-Missouri basketball game, Gov. Jay Nixon launched an effort to build 35 houses in tornado-devastated Joplin.
>Indiana rolls, ends 5-game skid against Purdue Victor Oladipo scored a career-high 23 points to help No. 20 Indiana defeat Purdue 78-61 on Saturday night and break a five-game losing streak to its in-state rival.
Sports News - ESPN
>Source: Fleck left NIU job to coach Bucs' WRs A day after backing out of an agreement with NIU, a source said P.J. Fleck is heading to Tampa.
>W. Virginia cancels Sept. 8 game vs. Florida St. West Virginia has decided to cancel its Sept. 8 football game at Florida State.
>Report: Rhodes' timeline contradicts Yale QB's Rhodes Trust officials suggest a Yale University quarterback would have known his candidacy for the prestigious scholarship was in jeopardy because of a sexual misconduct allegation, contrary to what he has said, a newspaper reports.
>Report: QB knew Rhodes candidacy was at risk Rhodes Trust officials suggest a Yale University quarterback would have known his candidacy for the prestigious scholarship was in jeopardy because of a sexual misconduct allegation, contrary to what he has said, a newspaper reports.
>Mularkey's son arrested on possession charge Chapel Hill police say the son of new Jacksonville Jaguars coach Mike Mularkey is among three former North Carolina athletes arrested for possession of cocaine.
>Source: Fleck left NIU job to coach Bucs' WRs A day after backing out of an agreement with NIU, a source said P.J. Fleck is heading to Tampa.
>W. Virginia cancels Sept. 8 game vs. Florida St. West Virginia has decided to cancel its Sept. 8 football game at Florida State.
>Report: Rhodes' timeline contradicts Yale QB's Rhodes Trust officials suggest a Yale University quarterback would have known his candidacy for the prestigious scholarship was in jeopardy because of a sexual misconduct allegation, contrary to what he has said, a newspaper reports.
>Report: QB knew Rhodes candidacy was at risk Rhodes Trust officials suggest a Yale University quarterback would have known his candidacy for the prestigious scholarship was in jeopardy because of a sexual misconduct allegation, contrary to what he has said, a newspaper reports.
>Mularkey's son arrested on possession charge Chapel Hill police say the son of new Jacksonville Jaguars coach Mike Mularkey is among three former North Carolina athletes arrested for possession of cocaine.
Xconomy Life Sciences
>Never Back Smug: A Lesson for Life Sciences From Newt GingrichNewt Gingrich comes across on TV as someone who radiates smugness. It?s that sense that he?s not just confident in his own abilities, but extremely satisfied with his talents and his utter superiority over mere mortals like you and me. I?m no political pundit, nor a psychologist, so I?ll let others analyze whether Newt is [...]
>Vertex Gets FDA Go-Ahead To Sell New Cystic Fibrosis Drug[Updated: 1:25 pm] Vertex Pharmaceuticals is now officially more than just a one-hit wonder. The Cambridge, MA-based biotech company (NASDAQ: VRTX), best known for its hepatitis C drug, has won clearance from the FDA to start selling a new twice-daily pill called ivacaftor (Kalydeco) for a rare form of cystic fibrosis. The FDA said today [...]
>Flagship Ventures Plans to Open Michigan OfficeCambridge, MA-based Flagship Ventures, a $900 million fund known for its successes with companies such as Accuri Cytometers and Acceleron Pharma, is planning to open an office in Michigan in the next six months, says Sean O?Donnell, VP at Credit Suisse?s Michigan office. The move comes after Venture Michigan Fund II (VMF II), a fund-of-fund which is [...]
>Calling All Boston-Area Marketing Mavens??or really just one great one: Xconomy needs your help. We?re busy cranking out terrific tech and life sciences journalism and putting on stellar events across the six cities in our network, and we?re looking for a kick-ass marketing coordinator to help us get the word out about all of it. Full details are here, [...]
>San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy?San Diego?s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected the Amylin?s drug twice before. An estimated 26 million people in the United States, or roughly 8 percent of the population, have type [...]
>Never Back Smug: A Lesson for Life Sciences From Newt GingrichNewt Gingrich comes across on TV as someone who radiates smugness. It?s that sense that he?s not just confident in his own abilities, but extremely satisfied with his talents and his utter superiority over mere mortals like you and me. I?m no political pundit, nor a psychologist, so I?ll let others analyze whether Newt is [...]
>Vertex Gets FDA Go-Ahead To Sell New Cystic Fibrosis Drug[Updated: 1:25 pm] Vertex Pharmaceuticals is now officially more than just a one-hit wonder. The Cambridge, MA-based biotech company (NASDAQ: VRTX), best known for its hepatitis C drug, has won clearance from the FDA to start selling a new twice-daily pill called ivacaftor (Kalydeco) for a rare form of cystic fibrosis. The FDA said today [...]
>Flagship Ventures Plans to Open Michigan OfficeCambridge, MA-based Flagship Ventures, a $900 million fund known for its successes with companies such as Accuri Cytometers and Acceleron Pharma, is planning to open an office in Michigan in the next six months, says Sean O?Donnell, VP at Credit Suisse?s Michigan office. The move comes after Venture Michigan Fund II (VMF II), a fund-of-fund which is [...]
>Calling All Boston-Area Marketing Mavens??or really just one great one: Xconomy needs your help. We?re busy cranking out terrific tech and life sciences journalism and putting on stellar events across the six cities in our network, and we?re looking for a kick-ass marketing coordinator to help us get the word out about all of it. Full details are here, [...]
>San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy?San Diego?s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected the Amylin?s drug twice before. An estimated 26 million people in the United States, or roughly 8 percent of the population, have type [...]
Yahoo Biotech News
>Sex & Parenting Genes Discovered in Mice (LiveScience.com) LiveScience.com - Men are from Mars and women are from Venus, but how did they get there? Our gender differences might be a function of how our brains react to hormones, a new study on mice suggests.
>Same Genes Key to Early & Late-Onset Alzheimer's: Study (HealthDay) HealthDay - THURSDAY, Feb. 2 (HealthDay News) -- People who develop Alzheimer's disease late in life may have the same gene mutations linked to the inherited, early onset form of the condition, according to a new study.
>Romney stock trades clash with divestment pledge (AP) AP - During his presidential campaign in 2007, Republican candidate Mitt Romney promised that a trust overseeing his financial portfolio would shed any investments that conflicted with GOP positions toward Iran, China, stem cell research and other issues.
>Stem Cell Therapy Shows Promise for Stroke, Studies Say (HealthDay) HealthDay - WEDNESDAY, Feb. 1 (HealthDay News) -- Treating stroke patients with stem cells taken from their own bone marrow appears to safely help them regain some of their lost abilities, two small new studies suggest.
>Gene Study Sheds Light on Body Clock's Link to Diabetes (HealthDay) HealthDay - MONDAY, Jan. 30 (HealthDay News) -- Researchers studying the link between diabetes and a hormone that affects your so-called "body clock" have identified a genetic mutation in the receptor for the hormone, melatonin, that may to boost the risk of the disease.
>Sex & Parenting Genes Discovered in Mice (LiveScience.com) LiveScience.com - Men are from Mars and women are from Venus, but how did they get there? Our gender differences might be a function of how our brains react to hormones, a new study on mice suggests.
>Same Genes Key to Early & Late-Onset Alzheimer's: Study (HealthDay) HealthDay - THURSDAY, Feb. 2 (HealthDay News) -- People who develop Alzheimer's disease late in life may have the same gene mutations linked to the inherited, early onset form of the condition, according to a new study.
>Romney stock trades clash with divestment pledge (AP) AP - During his presidential campaign in 2007, Republican candidate Mitt Romney promised that a trust overseeing his financial portfolio would shed any investments that conflicted with GOP positions toward Iran, China, stem cell research and other issues.
>Stem Cell Therapy Shows Promise for Stroke, Studies Say (HealthDay) HealthDay - WEDNESDAY, Feb. 1 (HealthDay News) -- Treating stroke patients with stem cells taken from their own bone marrow appears to safely help them regain some of their lost abilities, two small new studies suggest.
>Gene Study Sheds Light on Body Clock's Link to Diabetes (HealthDay) HealthDay - MONDAY, Jan. 30 (HealthDay News) -- Researchers studying the link between diabetes and a hormone that affects your so-called "body clock" have identified a genetic mutation in the receptor for the hormone, melatonin, that may to boost the risk of the disease.